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Abstract
Among the first white blood cells to respond to bacterial and fungal infections,
neutrophils are produced in the bone marrow, released into circulating blood,
and recruited to inflamed tissue. The cytokine granulocyte colony-stimulating
factor (G-CSF) is used clinically to induce neutrophil mobilization from the
marrow.

This process was previously demonstrated to require the STAT3

transcription factor (signal transducer and activator of transcription 3), the
principal signaling molecule activated upon G-CSF-binding of its receptor, but
the mechanism was unknown. The chemokines KC (Cxcl1) and MIP-2 (Cxcl2),
and their shared receptor CXCR2 (l8rb), also stimulate neutrophil mobilization, in
contrast to SDF-1 (Cxcl12), which contributes to neutrophil retention in the bone
marrow, requiring downregulation to promote neutrophil release. Using a murine
model with conditional STAT3 deletion in bone marrow, we demonstrate that
STAT3 regulates G-CSF-dependent changes in bone marrow chemokine and
chemokine receptor expression levels. We found that G-CSF/STAT3 signals
increase transcription of Cxcl1, Cxcl2, and Il8rb, and concomitantly suppress
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Cxcl12. Administration of a MIP-2-neutralizing antibody in vivo suppressed GCSF-stimulated upregulation of circulating neutrophil levels, indicating its critical
role in neutrophil mobilization. Consistent with this observation, STAT3-deficient
mice were more susceptible than wild type to infection with Listeria
monocytogenes, a bacterium that initiates a G-CSF-mediated immune response.
STAT3-deficient mice failed to upregulate circulating neutrophils after infection,
and demonstrated higher levels of bacterial infiltration in the liver, indicating that
impaired neutrophil mobilization contributes to an insufficient immune response.
Further analysis of molecular events that transpire upon STAT3-binding to the
Cxcl2 and Il8rb promoters indicates that G-CSF induces higher levels of
activating trimethylated lysine 4 (H3K4me3) modifications relative to repressive
trimethylated lysine 27 (H3K27me3) marks, suggesting G-CSF/STAT3 signals
stimulate an open chromatin configuration at these promoters. This is further
supported by the observation that pharmacologic inhibition of STAT3
phosphorylation blocked G-CSF-stimulated accumulation of H3K4me3 at target
promoters, indicating that STAT3 may contribute to accumulation of H3K4me3
marks. Taken together, our study demonstrates that G-CSF-mediated STAT3
regulation of bone marrow chemokine and chemokine receptor expression may
regulate neutrophil mobilization and indicates a potential role for STAT3 in
opening of the chromatin structure at target genes in neutrophils.
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Chapter 1: Introduction

1.1 Introduction to neutrophils

The neutrophil, the predominant circulating white blood cell type,
mediates inflammation as well as anti-bacterial and anti-fungal immunity (1).
Hallmark morphological features of neutrophils include the presence of granules,
classifying them as a type of granulocyte, and a multi-lobed nucleus, prompting
their designation as polymorphonuclear cells. Neutrophils, produced in the bone
marrow, are constantly released into peripheral blood under homeostatic
conditions, where circulating mature cells can be readily recruited to inflamed
tissue. Neutrophil effector functions include phagocytosis, respiratory burst, and
degranulation, which is the release of pre-formed molecules such as antibacterial peptides and proteases.

Recently, neutrophil extracellular traps

(NETs) have been characterized in which chromatin and granule components
are expelled from the neutrophil, forming sticky bundles that ensnare bacteria
(2). Insufficient neutrophil numbers or deficient neutrophil functions have clinical
implications in conditions such as severe congenital neutropenia and chronic
granulomatous disease, respectively.

Both conditions are characterized by

increased susceptibility to opportunistic infections that can be life threatening (3).
By contrast, unregulated accumulation of neutrophils in the tissue has been
implicated in chronic inflammatory conditions such as rheumatoid arthritis (4),
asthma (5), and chronic obstructive pulmonary disorder (6).

Both extremes
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underline the importance of proper regulation of the neutrophil response to avoid
pathological conditions.

Figure 1.1. The stages of neutrophil development. Developing from the
hematopoietic stem cell (HSC), the common myeloid progenitor (CMP), and the
granulocyte/macrophage progenitor (GMP), the myeloblast differentiates further
through the myelocyte stages before becoming a mature segmented neutrophil.
Azurophilic, or primary granules, are expressed first in the promyelocyte, before
acquisition of the specific, or secondary granules. Adapted from (7, 8).
The short half-life of circulating neutrophils, a matter of hours,
necessitates their constant replenishment from the bone marrow, where they
differentiate from the hematopoietic stem cell (HSC) in a process called
granulopoiesis (9).

After the HSC, common myeloid progenitor (CMP), and

granulocyte/macrophage progenitor (GMP) stages, neutrophils traverse multiple
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differentiated states to become a mature segmented cell, as shown in Figure
1.1. Blocks in granulopoiesis resulting in the accumulation of undifferentiated
cells are characteristic of myeloid leukemias, such as acute myeloid leukemia
and chronic myeloid leukemia (10). Each stage of neutrophil development is
distinguished morphologically by nucleus-to-cytoplasm ratio, the presence and
type of granules, and nuclear shape (7) (Figure 1.1). Granulopoiesis, as with
hematopoiesis in general, is governed by cytokines and transcription factors. In
the next two sections, I will introduce the major transcription factors involved in
granulopoiesis, and examine the contribution of cytokines to this process.

1.2. Transcription factors involved in granulopoiesis

Several

transcription

factors

are

critical

differentiation, as summarized in Figure 1.2.

for

proper

neutrophil

The ETS domain-containing

transcription factor PU.1 promotes the development of the myeloid lineage, and
is highly expressed in B cells, granulocytes and monocytes (11). Analysis of
PU.1-deficient embryos (due to embryonic lethality of PU.1 deletion) or mice
harboring a mutation in the PU.1 DNA-binding domain revealed significant
impairment in the development of lymphocytes, monocytes, and granulocytes,
while megakaryocytes and erythrocytes were intact (12, 13).

These data

suggest that PU.1 promotes development of the GMP, while repressing the
megakaryocyte-erythrocyte progenitor (MEP) (Figure 1.2).

PU.1 is therefore

thought to be important during progenitor commitment, although expression of
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PU.1 was found in all stages of neutrophil development, and increases with
maturation, with the highest expression levels found in the mature cell (14).

Figure 1.2. Transcription factors involved in neutrophil differentiation.
PU.1- and C/EBPα-deficiency results in a block in the CMP-to-GMP transition,
while deficiency in C/EBPε and Gfi-1 inhibits terminal neutrophil differentiation.

The CCAAT/enhancer-binding protein (C/EBP) family of transcription
factors is also important for proper myeloid cell development.

These family

members can form homo- or hetero-dimers with one another. C/EBP alpha
(C/EBPα), like PU.1, is a transcription factor predominantly expressed in
neutrophil progenitors (Figure 1.2).

C/EBPα-deficiency results in a lack of

mature neutrophils and eosinophils in embryos and newborn mice (15), while
conditional deletion of C/EBPα in adult mice (Mx-Cre-mediated) results in a
block in the CMP to GMP transition, resembling acute myeloid leukemia (16).
Taken together, these data reveal the importance of PU.1 and C/EBPα in the
commitment of neutrophil progenitors (Figure 1.2).

In confirmation of these

findings, C/EBPα is highly expressed in the early stages of neutrophil
development, such as in the myeloblast and promyelocyte, and drops
significantly in more mature cells (14). Another C/EBP family member, C/EBP
epsilon (C/EBPε), is highly expressed during granulopoiesis (17), and its
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deficiency results in a lack of functionally mature neutrophils (18) (Figure 1.2).
In contrast to the roles of C/EBPα and C/EBPε, C/EBP beta (C/EBPβ) does not
appear to affect steady-state granulopoiesis, but is instead thought to be
involved in emergency, or demand-driven granulopoiesis, which occurs, for
example, during infections that coincide with an elevation of G-CSF levels (19,
20). Additional C/EBP family members delta (C/EBPδ), gamma (C/EBPγ), and
zeta (C/EBPζ) are also reportedly expressed in cells of the myeloid lineage, but
these molecules have either not been studied extensively, or are thought to play
minor and/or redundant roles during granulopoeisis (14, 21).
Recently, the zinc-finger transcription factor Gfi-1 has been implicated in
neutrophil development.

Initially characterized in the development of

lymphocytes, high expression of Gfi-1 was later found in mature neutrophils (22).
It is thought that Gfi-1 may promote terminal differentiation of neutrophils while
antagonizing the development of monocytes (23). Similar to C/EBPε-deficiency,
Gfi-1 deficiency results in a lack of phenotypically mature neutrophils (18, 23)
(Figure 1.2).
While the presence of the transcription factors PU.1, C/EBPα, C/EBPε
and Gfi-1 is important during granulopoiesis, deficiency of certain cytokines can
have a severe impact on neutrophil development. Additionally, cytokines have
been shown to alter transcription factor expression levels, thereby affecting cell
fate (24). I will next examine the effects of cytokines on neutrophil development.
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1.3. Granulocyte colony-stimulating factor (G-CSF) and other cytokines
governing granulopoiesis

The cytokine granulocyte colony-stimulating factor (G-CSF) is the major
regulator of granulopoiesis, as evidenced by the significant loss of neutrophils in
G-CSF- or G-CSF receptor (G-CSFR)-deficient mice (25, 26).

However,

residual neutrophil levels in these mice, although at low levels, indicate that
other cytokines may compensate in vivo, such as Granulocyte-Macrophage
Colony-Stimulating Factor (GM-CSF) and Interleukin-6 (IL-6) (27, 28). While
GM-CSF is important for neutrophil differentiation in vitro (29), GM-CSF-deficient
mice exhibit normal hematopoiesis (30, 31), indicating the redundant function of
GM-CSF in vivo. In support of this finding, adult mice deficient in GM-CSF and
G-CSF exhibited similar levels of neutrophils as G-CSF-deficient mice (32).
Similar to the phenotype of GM-CSF-deficiency, deficiency in IL-6 exhibited
normal granulopoeisis under steady state conditions (33).

However, mice

deficient in G-CSF and IL-6 were more neutropenic than with G-CSF-deficiency
alone, indicating the contribution of IL-6 to granulopoiesis under compensatory
conditions in vivo (34).
G-CSF is present at very low levels in healthy individuals, and is rapidly
upregulated in the presence of infection (up to 20-fold increase) (35-37). G-CSF
can accelerate the cell cycle, allowing for rapid proliferation of neutrophil
progenitors (38, 39). G-CSF also drives the differentiation of neutrophils in the
bone marrow, their release into peripheral blood, and promotes pro-survival
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signaling (39, 40). These combined functions of G-CSF result in a rapid and
sustained elevation in neutrophil counts.
G-CSF is produced by endothelial cells, fibroblasts, monocytes/
macrophages and mesenchymal cells (41, 42).

Murine and human G-CSF

molecules are highly homologous, as recombinant human G-CSF can crossreact with murine G-CSFR (43).

The cytokines IL-1β, IL-3, IL-4, GM-CSF,

interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) can strongly
promote G-CSF production from these cell types, as does stimulation with
lipopolysaccharide (LPS) (42). In addition to these pathways, recent studies
indicate that macrophages and dendritic cells initiate a cascade of events that
results in G-CSF production.

Upon activation of their toll-like receptors,

macrophages and dendritic cells produce IL-23 in response to pathogens (44).
IL-23, in turn, stimulates IL-17 production from Th17 cells, a subset of CD4 T
cells lining mucosal surfaces. IL-17 then drives G-CSF production from cells
comprising the stroma, such as fibroblasts, epithelial, and endothelial cells (4547).

In response to bacterial pneumonia infection, IL-17 receptor-deficiency

resulted in reduced G-CSF levels, delayed neutrophil recruitment, and higher
mortality rates compared to wild type controls, indicating the importance of IL17-induced granulopoiesis in vivo (46).
Because G-CSF is the primary cytokine that drives granulopoiesis, it is
administered clinically to treat conditions of reduced levels of circulating
neutrophils, or neutropenia, under the trade names Neupogen, Granocyte, or
Neulasta; the latter is a pegylated form that is longer lasting in circulation (48).
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While congenital forms exist that have been present since birth, neutropenia can
also be induced, for example as a side effect of chemotherapeutics. Therefore,
recombinant G-CSF is often incorporated into chemotherapy regimens (49). GCSF is also used to mobilize stem cells into peripheral blood to facilitate
collection

for

transplantation,

and

is

thought

to

promote

survival

of

cardiomyocytes after myocardial infarction (50, 51). However, because G-CSF
treatment has yielded inconsistent results clinically and has been correlated with
onset of osteoporosis and malignant transformation of myeloid cells, attention
has turned to the study of the molecular pathways activated by G-CSF (52, 53).

1.4.

G-CSF receptor (G-CSFR) and downstream signal transduction

pathways

As illustrated in Figure 1.3, G-CSFR is a type I cytokine receptor, defined
as a single transmembrane protein containing a cytokine receptor homologous
(CRH) domain in the extracellular region consisting of four conserved cysteine
residues and a Trp-Ser-X-Trp-Ser (WSXWS) motif, and two conserved regions
in the intracellular region denoted as Box 1 and Box 2 (54, 55). In addition to
elements that define type I cytokine receptors, the G-CSFR also contains an
immunoglobulin-like (Ig-like) domain, as well as three fibronectin type III-like
(FNIII-like) domains in the extracellular region, and the intracellular domain
contains a third element called Box 3 (54, 55) (Figure 1.3).

The G-CSFR

structure closely resembles gp130, a single transmembrane protein that
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transduces downstream signals when hetero-dimerized with ligand-specific
alpha subunits for the cytokines IL-6, leukemia inhibitory factor (LIF) and
oncostatin M (OSM) (54).

G-CSFR and gp130 share 46.3% amino acid

homology; like G-CSFR, gp130 contains an Ig-like domain, FNIII-like domains,
and Box 3 (56).

Figure 1.3. G-CSFR structure and downstream signal pathways. The
extracellular region of the G-CSFR contains an immunoglobulin-like (Ig-like)
domain, a cytokine receptor homologous (CRH) domain with 4 conserved
cysteine residues and a conserved WSXWS motif, and 3 fibronectin type III
(FNIII)-like domains. The intracellular region, which mediates downstream
signal transduction, contains conserved Box 1, Box 2, and Box 3 motifs, and 4
tyrosine (Y) residues.
The membrane proximal region of the G-CSFR
cytoplasmic domain mediates growth signals, and has been linked to activation
of Jaks, STAT1, STAT5, and ERK1/2.
The tyrosine residues mediate
differentiation signals. Y704 and Y744 recruit STAT3, Y729 is a docking site for
SOCS3, a negative regulator of G-CSFR signaling, and Y764 associates with
Grb2, and is reported to activate p21Ras, as indicated. Modified from (57, 58).
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G-CSF binds with very high affinity to the G-CSFR (Kd ≈ 700 pM), which
homo-dimerizes upon ligation, resulting in a complex of two molecules of G-CSF
and two G-CSFR subunits (54, 59) (Figure 1.4[B-D]).

X-ray crystallography

revealed that each ligand molecule interacts with the CRH domain of one GCSFR subunit and the Ig-like domain of the second subunit, resulting in a
crossover configuration, as shown in Figure 1.4[B-D] (59).

The G-CSFR is

expressed on HSC, CMP, GMP, mature neutrophils and their progenitors, and
the level of expression increases upon maturation (60-62).

While other

hematopoietic and non-hematopoietic cell types have been demonstrated to
express G-CSFR, the profound loss of neutrophils in the G-CSFR knockout
indicates that its chief function is in this cell type (26).

Figure 1.4. Activation of Jak-STAT signal transduction. [A] Jaks are
constitutively associated with G-CSFR in the absence of ligand. [B] Ligand
binding occurs at a 2:2 ligand:receptor subunit stoichiometry, resulting in a
cross-over configuration of the receptor subunits. The resulting proximity of the
Jaks enable their trans-phosphorylation and activation. [C] Jaks phosphorylate
intracellular tyrosine residues of the G-CSFR (represented by stars). [D] STATs
interact with the phosphotyrosines via their SH2 domains, and become
phosphorylated by the Jaks. STAT dimers form, accumulate in the nucleus, and
regulate transcription of cytokine-responsive genes. Modified from (59, 63)
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Each G-CSFR subunit lacks intrinsic signaling capability, and signals
through constitutive association with Janus tyrosine kinases (Jaks), primarily
Jak1 (64-66). Box 1 in the membrane-proximal intracellular region of the GCSFR contains a proline-rich sequence thought to serve as a docking site for
Jaks (67). High affinity interactions between G-CSF and its receptor bring the
Jaks into proximity, resulting in their phosphorylation of one another, and
ultimately of tyrosine (Y) resides located in the intracellular domain of G-CSFR
(Figure 1.4). In humans, these tyrosine residues are Y704, Y729, Y744, and
Y764 (corresponding to Y703, Y728, Y743, and Y763 in the mouse), that once
phosphorylated, serve as docking sites for downstream signaling molecules,
predominantly the signal transducers and activators of transcription (STATs) (68,
69). While there are seven STAT family members, G-CSF stimulation results in
robust activation of STAT3, with activation of STAT1 and STAT5 occurring to a
lesser extent (65, 70, 71). Although it is widely accepted that G-CSFR signaling
chiefly activates Jak/STAT pathways, the G-CSFR has also been linked to
multiple components of mitogen-activated protein (MAP) kinase signaling
pathways (72-75).
STATs are transcription factors constitutively found in the cytoplasm, and
can interact with phosphorylated tyrosines of the G-CSFR through their Src
homology 2 (SH2) domains, enabling their phosphorylation by Jaks (Figure
1.4[D]). Upon their activation, STAT family members homo- or hetero-dimerize,
as their SH2 domains possess higher affinity for one another’s phosphorylated
residues when compared to those of the cytokine receptor (76).

Dimers of
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STATs accumulate in the nucleus, where they bind DNA and activate
transcription (76).
STAT3, as with other STAT family members, contains coiled-coil, DNA
binding, linker, SH2, and transactivation (TAD) domains, as shown in Figure 1.5
(63).

The carboxy-terminal TAD contains the critical tyrosine and serine

residues that can become phosphorylated (63). The DNA binding domain of
STAT3 binds the consensus sequence TTN(3-7)AA (77, 78), although recent
computational studies followed by candidate validation approaches indicate that
the STAT3 recognition sequence may not be as rigid as once believed (79).

Figure 1.5. A schematic of the structure of STAT3. STAT3 contains a
coiled-coil, DNA binding, linker, SH2, and transactivation (TAD) domains. The
C-terminal TAD contains the critical tyrosine (Y705) and serine (S727) residues
that become phosphorylated upon STAT3 activation. Adapted from (63).
STAT3 is recruited to Y704 and Y744 of the G-CSFR, although receptor
truncation studies demonstrated that Y704 was sufficient for STAT3 activation
(65, 71, 74).

In vitro, activation of STAT3 appears to drive neutrophil

differentiation, as judged by induction of neutrophil marker genes and
morphological changes associated with maturation (80, 81). However, in vivo
studies revealed a more complex role for STAT3 in regulation of granulopoiesis,
which will be discussed in the next section.
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1.5. Role for STAT3 in the regulation of granulopoiesis in vivo
Previous in vitro models indicated that G-CSFR-activated STAT3 is a
major regulator of granulopoiesis (65, 71, 74, 80, 81). To assess the role of
STAT3 in the G-CSFR signaling pathway in vivo, the first studies used G-CSFR
deletion mutants expressed in mice which replaced the endogenous gene
(Figure 1.6). In one such construct, designated d715, a premature stop codon
was introduced in the G-CSFR to mimic the truncated receptor found in some
cases of the clinical condition severe congenital neutropenia.

In the d715

receptor, the tyrosine residues Y729, Y744 and Y764 are deleted, while the
STAT3 docking site Y704 remained intact, as shown in Figure 1.6[B] (82, 83).
Steady-state granulopoiesis was normal in d715 mice, as judged by neutrophil
numbers in blood and bone marrow (82, 83).

However, d715 mutant mice

demonstrated an enhanced response to G-CSF as compared to wild type
controls, producing an increased absolute number of progenitors and enhanced
proliferative responses, resulting in increased peripheral neutrophils (82, 84).
These results indicate that Y704 is sufficient in steady state and G-CSF-driven
granulopoiesis, and points to the recruitment of negative regulators by the
deleted region of the G-CSFR (most likely SOCS3, or suppressor of cytokine
signaling).
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Figure 1.6. Deletion mutants of G-CSFR used in mouse models. [A] GCSFR-deficient (Csf3r-/-) mice were generated by deletion of exons 3-8. [B] The
G-CSFR d715 mutant was generated by introduction of a premature stop codon,
deleting three intracellular tyrosine (Y) residues, leaving only Y704. [C] In the
d715F mutant, Y704 is mutated to phenylalanine (F).
To understand the role of the remaining STAT3 recruitment site (Y704),
this tyrosine residue was mutated to phenylalanine (F), generating the d715F
mutation, as shown in Figure 1.6[C] (83). Mice expressing the d715F mutation
were severely neutropenic, as circulating neutrophil levels are similar to those in
the G-CSFR-deficient mice. In contrast to the findings in d715 mice, G-CSF
failed to upregulate circulating neutrophils in d715F mice, and did not induce
proliferation of hematopoietic progenitors (83). These proliferative defects were
partially restored upon introduction of a constitutively active STAT3 isoform
(STAT3C) into d715F progenitor cells in vitro (83). These studies agree with
results from earlier in vitro work, which indicated the importance of STAT3 in
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mediating G-CSF-responsive proliferation and differentiation signals (65, 71, 74,
80, 81).
To directly examine the function of STATs in granulopoiesis, STATdeficient mouse models were generated. Although G-CSFR stimulation results
in activation of STAT1, STAT3, and STAT5 (65, 70, 71), deletion of STAT1 or
STAT5 has minimal effect on granulopoiesis in vivo (85, 86). These results, in
context of the results found in the d715F mutant mice, further support the
importance of STAT3 in this pathway. Because deletion of STAT3 results in
embryonic lethality (87), mice were generated in which STAT3 was conditionally
inactivated in the hematopoietic system (88-91). As opposed to the neutropenia
observed in d715F mice, a model in which G-CSF-responsive STAT3 activation
is suppressed, mice with hematopoietic deletion of STAT3 exhibit generalized
inflammation and neutrophilia, or increased circulating neutrophils (83, 88, 91).
As compared to wild type animals, mice with conditional STAT3 deletion have
increased amounts of morphologically mature neutrophils (band and segmented
cells) in the bone marrow, although levels of myeloid progenitor cells and
immature granulocytes were similar, suggesting that STAT3 is a negative
regulator of terminal neutrophil differentiation (88). Together with the observed
neutrophilia in STAT3-deficient mice, these results suggested that STAT3 is
required to suppress neutrophil production in homeostatic conditions.

This

phenotype is similar to that of aged mice with hematopoietic deletion of SOCS3,
a STAT3 target gene that negatively regulates G-CSFR signal transduction (92,
93).

Therefore, these data indicate that STAT3 and SOCS3 are important
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negative regulators of steady-state granulopoiesis.

However, recent studies

indicate that the role for STAT3 in granulopoiesis may be more complex than
these findings initially indicated.
Emergency granulopoiesis occurs upon infection or administration of GCSF, resulting in enhanced cell cycle progression of granulocytic progenitors in
the bone marrow, increased neutrophil production, and the release of mature
neutrophils into circulating blood (35, 39). After repeated exposure to G-CSF,
Tg[Tek-cre]12Flv, Stat3f/Δ mice, termed herein as STAT3-deficient mice, fail to
increase immature granulocyte amounts in bone marrow, resulting in a skewed
ratio of immature:mature cells in bone marrow, blood and spleen (91). This
effect was not observed in myeloid-specific SOCS3-deficient mice, which
indicates that the role for STAT3 in G-CSF-driven emergency granulopoiesis is
independent of SOCS3 (91). In support of these findings, STAT3 was found to
promote G-CSF-dependent cell cycle progression and differentiation of
immature granulocytes (20).

Moreover, the proliferation of multipotent and

committed myeloid progenitors in response to G-CSF or following infection by
Listeria monocytogenes, a bacterial pathogen that is regulated by G-CSF signals
in vivo (25, 94), is dependent upon STAT3 (20). These data indicate that STAT3
is an important regulator of hematopoietic progenitor proliferation during
emergency granulopoiesis driven by G-CSF or bacterial infection (20).
The phenotype of impaired demand-drive neutrophil response in STAT3deficient mice is similar to Cebpb-/- mice, in which C/EBPβ, an essential
regulator of emergency granulopoiesis, is deleted (19), suggesting that the
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functions of STAT3 and C/EBPβ are related. Additionally, Cebpb was recently
described as a STAT3-target gene (20). C/EBPβ contributes to the emergency
granulopoiesis response, in part, by affecting expression of c-myc, an important
regulator of the cell cycle (19). The proximal promoter region of c-myc contains
consensus binding sites for C/EBPα and C/EBPβ, which demonstrate opposing
roles in c-myc regulation (20).

Expression of c-myc is suppressed when

C/EBPα interacts with its promoter, and is relieved when G-CSF/STAT3 signals
stimulate expression of C/EBPβ, inducing transcription (20).

This pathway,

illustrated in Figure 1.7, provides a molecular mechanism by which G-CSF
signaling via STAT3 and C/EBPβ stimulates neutrophil progenitor proliferation
during emergency granulopoiesis.

Figure 1.7. Regulation of c-myc by STAT3 and C/EBPβ. G-CSFR/STAT3
signals induce expression of C/EBPβ, which associates with the c-myc proximal
promoter. This relieves suppression of c-myc by C/EBPα, resulting in sustained
c-myc expression. Modified from (20).

1.6. General mechanisms of transcriptional regulation

The transcription factors discussed thus far, such as STAT3 and the
C/EBP family members, are important regulators of gene expression. While it is
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accepted that the binding of these factors regulates transcriptional activity,
recent studies have demonstrated that this process is far more complex than
initially thought, with much more yet to be revealed. In order to provide a more
in-depth view of the transcriptional regulation process, I will discuss the
organization of DNA, chromatin dynamics, and the pre-initiation complex in this
section, all which coordinate with transcription factors to promote gene
expression.
A nucleosome is formed when approximately 150 basepairs of DNA is
tightly wrapped around a histone core, an octamer consisting of two of each
subunit: H2A, H2B, H3, and H4 (95). These histone subunits have tails at the
amino termini that are easily accessed and modified post-translationally, such as
by phosphorylation, ubiquitination, acetylation, sumoylation, and methylation, all
which affect transcriptional activity (96). The chromatin modification that is best
understood is acetylation, which is mediated by histone acetyltransferases
(HATs) and histone deacetylases (HDACs). Addition of acetyl groups is thought
to neutralize the interactions between DNA and histones, as DNA is negatively
charged and histones are positively charged, regulating the accessibility to the
transcription machinery (97).

Recently, much attention has focused on histone

methylation, but it is poorly understood how methylation is regulated, and how it
affects transcription.

Methylation may affect DNA accessibility in a manner

similar to acetylation, however, methyl groups are small and uncharged (96).
Instead, it is thought that methylated lysine residues recruit regulators of
transcription by direct interaction with their chromodomains (96).
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Methylation of histone subunits, catalyzed by histone methyltransferases
(HMTs), can occur at two residues. Arginine (R), which can be mono- and dimethylated, has been associated only with transcriptional activity. On the other
hand, lysine (K), which can be mono-, di- or tri-methylated, can be associated
with transcriptional activation and repression depending on the context (98, 99).
The most widely studied modifications are of histone subunit H3, in which trimethylated lysine 4 (denoted as H3K4me3) and lysine 27 (H3K27me3) correlate
with regions of active and silent transcription, respectively (96). H3K4me3 tends
to accumulate at the promoters of active genes, and has been shown, for
example, to recruit chromodomain helicase DNA-binding protein 1 (CHD1), an
enzyme with chromatin remodeling activity (100, 101).

On the other hand,

H3K27me3 is found throughout heterochromatin, and is associated with X
chromosome inactivation (102).

H3K27me3 has been shown to recruit

Polycomb Repressive Complex 2 (PRC2) through its chromodomain, which
mediates additional H3K27 tri-methylation and transcription repression (103).
After the chromatin is remodeled and the DNA is more accessible, a preinitiation complex (PIC) forms at the proximal promoter, which is composed of
the general transcription factors TFIID, TFIIB, TFIIF, TFIIE, and TFIIH. TFIID,
which binds the promoter first, contains the TATA-binding protein (TBP), and
TBP-associated elements (TAA). Next, TFIIB binds, recruiting RNA polymerase
II (Pol II), and allows TFIIF to associate.

TFIIE and TFIIH are required for

transcription initiation (104) (Figure 1.8). The carboxy-terminal domain of the
largest subunit of Pol II is made of the sequence YSPTSPS, which is repeated
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52 times in mammals (Figure 1.8). In a hypophosphorylated state, Pol II can
readily bind DNA. Upon its initiation, the serine (Ser) residue in the fifth position
of the CTD repeat is phosphorylated (pSer5), and phosphorylation of the Ser in
the second position (pSer2) is associated with Pol II elongation. The initiation of
transcription by the PIC and Pol II is illustrated in Figure 1.8.

Figure 1.8. Transcription initiation by the PIC and Pol II. The transcription
pre-initiation complex (PIC) begins with the interaction of the general
transcription factors TFIID (D) to the TATA box upstream of the transcription
start site (indicated by the arrow). Sequentially, TFIIA (A), TFIIB (B) and TFIIF
(F) bind, allowing recruitment of RNA Polymerase II (Pol II). TFIIE (E) and TFIIH
(H) assemble, and the serine (S) residue in the fifth position of the Pol II
carboxy-terminal domain becomes phosphorylated, signaling transcription
initiation. Modified from (105).
The efficiency of transcription initiation is regulated through the action of
transcription regulators, such as activators, repressors, enhancers, and
silencers, all of which can have direct or indirect effects on the PIC (106). While
some

transcription

factors

have

demonstrated

direct

association

with

components of the PIC (107), the relationship between transcription regulators
and the PIC is not fully understood. Binding of transcriptional regulators requires
accessibility to DNA, but it is unknown how this access is gained.

Some
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transcriptional regulators are thought to bind DNA in its nucleosome state, and
are known as pioneer transcription factors (99). On the other hand, it is believed
that the majority of transcription factors require the action of chromatin
remodeling enzymes to mediate accessibility. While some transcription factors
are shown to directly interact with histone modifying enzymes, such as the
acetyltransferase p300 (108-112), it is not understood how most transcription
factors recruit these enzymes.
It is not fully understood how transcription is regulated in neutrophils, a
particularly interesting model to study given the burst of gene expression
required for their effector functions (113).

Additionally, little is known of the

effect of histone modifications during the development of neutrophils, or in
neutrophil functions such as mobilization, which will be discussed in the next
section.

1.7. Neutrophil mobilization
Neutrophil mobilization, the release of neutrophils from bone marrow to
blood, is necessary under steady state conditions to maintain proper circulating
levels (114).

Under inflammatory conditions, circulating neutrophil amounts

need to be rapidly increased, as neutrophils are the first recruited cells to sites of
infection (1). Mobilization involves a complicated progression of steps, involving,
among other processes, abrogation of retention signals in the bone marrow,
migration through hematopoietic niches of the marrow, and entry into the
vascular system (114).

The molecular events of this pathway are not fully
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understood, which is exploited clinically in the use of recombinant G-CSF to treat
neutropenias.
The administration of G-CSF is sufficient to induce rapid mobilization of
neutrophils out of the bone marrow into circulating blood (115). Kinetics were
established in rats, indicating that neutrophilia is induced 30 minutes after a
single injection of G-CSF, peaking at 12 hours, and pretreatment levels are
restored within 30-36 hours (116). G-CSF had no effect on circulating neutrophil
amounts in studies utilizing Csf3r-/- mice that are deficient in G-CSFR or GCSFR/erythropoietin receptor (EpoR) chimeric mice, in which the cytoplasmic
tail of the G-CSFR is replaced by the cytoplasmic tail of the EpoR.

These

findings indicate the necessity of the G-CSFR, as well as its downstream
signaling pathways, in the neutrophil mobilization process (115). To map the
region of the G-CSFR required for neutrophil mobilization, d715 and d715F
mutant mice were used as described in Section 1.4, in which the carboxyterminal 96 amino acids were truncated, leaving one remaining intracellular
tyrosine residue (d715), or its mutation to phenylalanine (d715F) (Figure 1.6[B]
and [C]). The d715F mice exhibited similar circulating neutrophil levels as wild
type in response to G-CSF, indicating that STAT3 may be dispensable in this
pathway, since the recruitment of STAT3 to the G-CSFR is abrogated in these
mice (115). By contrast, d715 mice demonstrated approximately four-fold higher
levels, revealing the requirement of the membrane-proximal 87 amino acids of
the G-CSFR. These findings also suggest the presence of a negative regulator
in the deleted segment (115). Bone marrow chimeras utilizing Csf3r-/- and wild
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type mice revealed that G-CSFR expression is required within the bone marrow
compartment, not in stromal cells, to mediate this mobilization response (115).
G-CSFR expression was not required on neutrophils to mediate neutrophil
mobilization in response to G-CSF, indicating the possible role of trans-acting
factors, believed to come from monocytes (115, 117). However, these data are
from hematopoietic stem and progenitor cell mobilization studies (117) and are
not conclusive evidence of the mechanism of neutrophil mobilization.
Another important aspect of neutrophil mobilization that is regulated by GCSF is the SDF-1/CXCR4 axis.

The chemokine SDF-1 (CXCL12) is

constitutively expressed in the bone marrow, and contributes to neutrophil
retention by interacting with its receptor CXCR4 expressed on the surface of
neutrophils (118, 119). G-CSF treatment correlates with downregulation of SDF1 and CXCR4 (120-122). SDF-1 is thought to be expressed by osteoblasts and
endothelial cells (121), and can be cleaved by the proteases neutrophil elastase,
cathepsin G, and matrix metalloproteinase 9 (MMP-9), which increase in the
serum after G-CSF administration (123-125).

G-CSF may also regulate the

expression of SDF-1 by regulating osteoblast abundance (121, 126).
STAT3-deficient mice were found to have impaired acute neutrophil
mobilization in response to G-CSF (91), indicating that STAT3 regulates
important factors mediating neutrophil retention and/or release in the bone
marrow, contrary to results from d715F mice (115). These factors are most
likely chemokines and chemokine receptors, which will be discussed in the
following section.
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1.8. Chemokines and their receptors
Chemokines are subset of cytokines that play an important role in the
activation and/or chemoattraction of leukocytes, and signal by interacting with
seven-transmembrane G protein-coupled receptors (127).

A nomenclature

system was introduced that grouped chemokines and their receptors based on
the position of conserved cysteine residues in the N-terminus (C, CC, CXC,
CX3C) (128). CXC chemokines that contain a conserved sequence of glutamic
acid (E), leucine (L), and arginine (R) immediately upstream of CXC, are
denoted as ELR-CXC chemokines, and are potent neutrophil chemoattractants.
In the human, ELR-CXC chemokines are GROα (CXCL1), GROβ (CXCL2),
GROγ (CXCL3), ENA-78 (CXCL5), GCP-2 (CXCL6), NAP-2 (CXCL7), and IL-8
(CXCL8) (128).
Chemokines play opposing roles in neutrophil function by mediating
retention in the bone marrow, as well as stimulating their release into circulating
blood and subsequently inducing trafficking to sites of inflammation in tissues
(127). As mentioned in the previous section, the chemokine SDF-1 (CXCL12) is
constitutively expressed in the bone marrow, while its receptor CXCR4 is
expressed on neutrophils and other hematopoietic cells (118, 119).

Mice

deficient in SDF-1 or CXCR4 demonstrate impaired myelopoiesis in the fetal
liver and bone marrow, and chimeras generated with CXCR4-deficient fetal liver
cells similarly have reduced levels of B cell and granulocytic precursor cells in
the bone marrow (118, 119). However, these CXCR4-deficient chimeric mice
have higher levels of immature circulating B cells and granulocytes, indicating
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the importance of the SDF-1/CXCR4 axis in the retention of immature cells in
the bone marrow (119). It has been shown that G-CSF treatment correlates with
downregulation of SDF-1 and CXCR4, little is known about the molecular
regulation of this pathway (120-122). The importance of the SDF-1/CXCR4 axis
is demonstrated clinically in warts, hypogammaglobulinemia, infections, and
myelokathexis, or WHIM syndrome. These patients exhibit truncation mutations
in CXCR4, contributing to the retention of their neutrophils in the bone marrow
(129). Lymphocyte numbers are reduced and lymphocyte functions are also
affected, resulting in susceptibility to viral and bacterial infections (129).
By contrast, CXCR2, also known as interleukin-8 receptor (IL-8R) in
humans, is the major chemokine receptor expressed on the murine neutrophil
and mediates neutrophil migration (130). The ligands in the mouse are KC
(CXCL1) and MIP-2 (CXCL2), which are potent neutrophil chemoattractants
(130). When CXCR2 is knocked out, neutrophil recruitment to infected tissues is
severely impaired, thereby rendering the host susceptible to pathogens (130,
131). However, CXCR2 has been implicated in many inflammatory disorders in
which unregulated neutrophil recruitment has contributed to tissue damage and
even death (132). Furthermore, the role of CXCR2 in angiogenesis, wound
healing, and cancer is well documented (132-134). Because STAT3-deficient
neutrophils exhibit impaired migration in response to CXCR2 ligands, further
study is required to understand the role of STAT3 in this pathway (91).
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1.9. Hypothesis
The requirement for STAT3 in the G-CSF mobilization pathway was
previously demonstrated by our group; however, the mechanism was not fully
understood (91).

We hypothesize that G-CSF/STAT3 signals regulate the

transcription of chemokines and chemokine receptors, contributing to the
neutrophil mobilization response. In Chapter 3, we will examine role of G-CSF
and STAT3 in regulating the expression of the chemokines MIP-2 (CXCL2) and
SDF-1 (CXCL12), which affect neutrophil release and retention, respectively.
Chapter 4 will explore the mechanism by which G-CSF and STAT3 control
expression of CXCR2, the receptor for MIP-2. In Chapter 5, we will examine the
molecular events that occur upon STAT3 activation at the promoter level.
Taken together, our data suggest the mechanisms by which STAT3 controls the
neutrophil migratory response to CXCR2 and its ligand MIP-2 (CXCL2).
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Chapter 2: Materials and Methods
Bone marrow STAT3-deficient mice, neutrophil isolation
Hematopoietic STAT3-deficient mice were generated by breeding Tg(Tekcre)12Flv (135) and Stat3f/Δ (136) mice. For genotyping, genomic DNA was
isolated from tails, and analyzed by PCR using previously published primer
sequences (135, 137). Littermate or aged-matched control mice, in which both
STAT3 alleles were intact, were used between 5-8 weeks of age. C57BL/6NCr
mice were obtained from the National Cancer Institute (NCI-Frederick, MD). All
mice were maintained in a specific pathogen free (SPF) facility and used in
accordance with the Institutional Animal Care and Use Committee (IACUC)
guidelines at UT M. D. Anderson Cancer Center (UT MDACC).

Peripheral blood samples were collected into ethylenediaminetetraacetic acid
(EDTA)-coated Vacutainer® tubes (Becton Dickinson) after retro-orbital
puncture, and complete blood counts were determined using automated
counting by the UT MDACC Department of Veterinary Medicine & Surgery.

Bone marrow cells were isolated from femurs and tibiae, and red blood cells
were lysed using Red Blood Cell Lysing Buffer (Sigma).

Cells were then

resuspended in PBS containing 2% fetal bovine serum (FBS), before labeling
with fluorescein isothiocyanate (FITC)-conjugated anti-Gr-1 (BD Biosciences)
and

allophycocyanin

(APC)-conjugated

anti-CD115

(eBioscience);

Gr-1
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negative, CD115+, Gr-1lo CD115- and Gr-1hi CD115- populations were sorted
using a BD FACSAria.

To isolate endothelial cells, osteoblasts, and hematopoietic cells, femurs, tibiae,
and iliac crests were isolated and minced after removal of the bone marrow.
Bone fragments were incubated in PBS containing 3-mg/mL type II collagenase
(Worthington) at 37°C for 2 hours with agitation.

Cells were labeled with

biotinylated antibodies against the lineage markers B220, CD11b, Gr-1, CD3,
and Ter119, and then APC-conjugated streptavidin was used to exclude the
lineage-positive cells (lin). The following antibodies were also added: Pacific
Blue-conjugated anti-CD45, FITC-conjugated anti-CD31, and Phycoerythrin
(PE)-conjugated anti-CD51 (all antibodies were from eBioscience).

Samples

were detected on a BD FACSAria for sorting into the following populations: lin+,
lin- CD45-CD31+endothelial cells, lin- CD45-CD31-CD51+osteoblasts, and
lin- CD45+ hematopoietic cells.

Flow cytometry
For CXCR2 staining, cells used were isolated from bone marrow as described
above, then resuspended in PBS with 2% FBS and labeled with FITCconjugated anti-Gr-1 (Pharmingen) and PE-conjugated anti-CXCR2 (R&D
Systems). Samples were acquired using a BD FACSCalibur or BD LSR II, and
the data were analyzed using FlowJo (Tree Star).
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G-CSF and anti-MIP-2 administration in vivo
Following dilution in sterile PBS containing 0.1% low endotoxin bovine serum
albumin (BSA, Sigma), recombinant human G-CSF (Amgen) was administered
by subcutaneous injection (250µg/kg). 20µg of anti-mouse MIP-2 antibody or
IgG2B control (R&D Systems) was diluted in sterile PBS, as suggested by the
manufacturer, and administered by intravenous injection 30 minutes before
administration of G-CSF.

RNA isolation, real-time PCR
Total RNA was isolated from cells as indicated using Tri-Reagent® (Molecular
Research Center), and reverse transcribed using iScript cDNA Synthesis kit
(Bio-Rad).

Real-time PCR was performed using iQ SYBR Green Supermix,

detected on the iQ5 or CFX96 Real-Time PCR Detection Systems and analyzed
using iQ5 Optical System Software or CFX Manager Software, respectively (BioRad), following the manufacturer’s recommendations.

Threshold cycle (CT)

values for each gene were normalized to the Rpl13a housekeeping gene to
measure relative mRNA expression (ΔCT).

CT values from chromatin

immunoprecipitation samples were normalized to input control.

Relative

expression was determined using the following formula: 1.8^ΔCT, as described
in

(138).

Primers

ATAGCCACACTCAA-3’,

used
Cxcl1

were

Cxcl1

Reverse

Forward

5’-CCGAAGTC-

5’-GCAGTCTGTCTTCTTTC-

TCCGTTAC-3’; Cxcl2 Forward 5’-AGACAGAAGTCATAGCCACTCTCAAG-3’,
Cxcl2 Reverse 5’-CCTCCTTTCCAGGTCAGTTAGC-3’; Cxcl12 Forward 5’-
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GAGAGCCACATCGCCAGAG-3’,

Cxcl12

Reverse

5’-TTTCGGGTCAA-

TGCACACTTG-3’; Il8rb Forward 5’-AGCAAACACCTCTACTACCCTCTA-3’,
Il8rb Reverse 5’-GGGCTGCATCAATTCAAATACCA-3’; Rpl13a Forward 5’GAGGTCGGGTGGAAGTACCA-3’,

Rpl13a

Reverse

5’-TGCATCTTGGC-

CTTTTCCTT-3’.

ELISA
Gr-1hi neutrophils were isolated from the bone marrow, as described above, and
cultured in RPMI containing 1% low endotoxin BSA (Sigma) and 1X AntibioticAntimycotic (Invitrogen) and stimulated with 25ng/ml rhG-CSF (Amgen), where
indicated. Supernatants were isolated and analyzed for MIP-2 expression by
ELISA using Mouse CXCL2/MIP-2 DuoSet (R&D Systems) following the
manufacturer’s instructions.

32D cell culture, retroviral transduction
The retroviral transfer vector pMX-G-CSFR-IRES-GFP was provided by Dr.
Huiyuan Zhang.

Retroviruses were generated by the introduction of the

following plasmids in 293T cells by calcium phosphate transfection: transfer
vector pMX-G-CSFR-IRES-GFP, pCMV-Gag-Pol packaging plasmid, and
pHCMV-G plasmid encoding VSV.G envelope protein.

12 hours post-

transfection, the media were replaced, and the supernatant was harvested 48
hours later.

32D cells expressing human G-CSFR (32D.G-CSFR) were

generated by retroviral transduction using viral supernatants, with the addition of
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4µg/ml Polybrene® (Hexadimethrine bromide, Sigma), and centrifuged at 2500
rpm for 90 minutes at room temperature. GFP-G-CSFR+ cells were enriched by
sorting using a BD FACSAria.

Cells were maintained in RPMI (Invitrogen)

supplemented with 10% FBS and 5-10% WEHI-conditioned media, as a source
of IL-3.

Untreated samples were generated by culturing 32D.G-CSFR in

RPMI/10% FBS for at least 4 hours. Where indicated, cells treated with 25ng/ml
rhG-CSF (Amgen) diluted in RPMI/10% FBS.

Identification of the Il8rb and Cxcl2 promoters, reporter assays
The putative proximal promoters for Cxcl2, Cxcl12, and Il8rb were identified
using Ensembl, and the putative STATx sites were found using TFSEARCH
(http://www.cbrc.jp/research/db/TFSEARCH.html).

The

putative

promoter

sequences were amplified using AccuPrime™ Pfx DNA Polymerase (Invitrogen)
and

the

following

primers:

ACCCACAACTATC-3’

and

CTGAGGTCCCGAGA-3’;
AGCTGAGAGG-3’and
CCGATGGGGA-3’.

Il8rb
Il8rb

Cxcl2
Cxcl2

Forward

5’-GGAGGTACCCTCAG-

Reverse

5’-GGAAGATCTGGCT-

Forward
Reverse

5’-GGAGGTACCGCACAGCA-

5’-GGAAGATCTGACCTGGGCTA-

Fragments were cloned into the pGL3-Basic plasmid

(Promega) using KpnI and BglII restriction sites. The mutation in the STATx site
was induced by PCR-based mutagenesis. Sequences were confirmed by the
UT MDACC DNA Core Analysis Facility.
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32D.G-CSFR cells were electroporated with 2 µg of the appropriate reporter
construct, 4 ng pTK-Renilla, and 0.5-1 µg of any additional plasmids, as
indicated. The Cell Line Nucleofector® Kit V (Lonza) and The Nucleofector®
Device (Lonza) were used following the manufacturer’s instructions. Cells were
then plated in RPMI/10%FBS/5-10% WEHI-conditioned media. After 18 hours,
cells were washed, and treated with 25ng/ml rhG-CSF (Amgen) for 6 or 12
hours, as indicated, prior to measurement of luciferase activity using the DualLuciferase Reporter Assay System (Promega). In brief, cells were washed with
PBS, and lysed with 1X Passive Lysis Buffer. Then, samples were mixed with
Luciferase Assay Buffer, and firefly luciferase activity was measured by the
Sirius Luminometer (Berthold Detection Systems). After addition of the Stop &
Glo reagent, renilla luciferase activity was measured. Data were analyzed as a
ratio of firefly light units:renilla light units.

Additional plasmids used were:

pRc/CMV-STAT3, encoding wild type STAT3 (from Dr. James Darnell); pMXSTAT3-DN-IRES-GFP, encoding a dominant negative form of STAT3, which
contains mutations in critical DNA binding residues [derived from pBABESTAT3-DN from Dr. Curt Horvath (20)]; and pRV-KM C/EBPα (from Dr. Chen
Dong).

Chromatin immunoprecipitations (ChIP)
The Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore) was used
following the manufacturer’s instructions with the following antibodies: normal
rabbit-IgG control (SantaCruz), anti-STAT3 c-20 antibody (SantaCruz), anti-
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trimethyl-histone

H3

(Lys4;

Millipore),

anti-trimethyl-histone

H3

(Lys27;

Millipore), anti-histone H3 (Abcam), and anti-RNA pol II CTD pSer5 (Active
Motif).

Primers

used

were

as

follows:

Cxcl2

Forward

5’-

GGTCACTTCAGCGCAGAC-3’, Cxcl2 Reverse 5’- TCTGAGGTCCCGAGAGCT3’; Cxcl12 Forward 5’-CTCTTGTGTACAGCCTGAGA-3’, Cxcl12 Reverse 5’GTCATCAGTGGAGACCTA-3’;

Il8rb

5’‐CTCCCAAGTTAGGTAG-

CATTTCCAC-3’,

Il8rb

Socs3

5’-CACAGCCTTTCAGTGCAGAG-3’,

Forward

Reverse

Forward

5’-TACCTGTTTGCCTGTAGGCAGGTA-3’;
Socs3

Reverse

5’-

GCGAATCAGGCAAAGGAC-3’. For detection of RNA pol II CTD pSer5, the
following primers were utilized: Il8rb Forward 5’- CCCAGAACAGCCTAGCCA-3’,
Il8rb Reverse 5’-GGCTCCCAACTCTCTGTG-3’; Cxcl2 Forward 5’-GACCCTGAGCTCAGGGAA-3’, Cxcl2 Reverse 5’- AGTGTGGCTGGAGTCTGG-3’.

Chemotaxis assays
Bone marrow neutrophils were resuspended in DMEM (Invitrogen) containing
0.1% low endotoxin BSA (Sigma) and plated in the upper chamber of 3µm
Transwells® 6.5mm diameter inserts with polycarbonate membranes (Corning).
DMEM/BSA in the absence or presence of 250 ng/ml MIP-2 was placed in the
lower chamber. After incubation for 3 hours at 37°C, cells that migrated to the
lower chamber were counted.
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Immunoblotting
Whole cell lysates were generated using Laemmli lysis buffer (80 mM Tris-Cl pH
6.8, 2% SDS, 15% glycerol, 1% β-mercaptoethanol, 0.01% bromophenol blue)
and heat-denatured at 100°C. Samples were separated using SDS-PAGE, and
transferred to nitrocellulose membranes. After blocking in 5% nonfat dry milk for
1 hour at room temperature, membranes were incubated overnight at 4°C in
primary antibody diluted in blocking buffer.

Antibodies used were against

STAT3 c-20 (SantaCruz), phospho-STAT3 Y705 (Cell Signaling), C/EBPα 14AA
(SantaCruz), Histone H3 (Abcam).

After washing in PBS/0.1% Tween-20

(Sigma), membranes were incubated with the appropriate horseradish
peroxidase (HRP)-linked secondary antibody (Amersham).

Samples were

detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce)
before exposure to radiographic film.

Infection with Listeria monocytogenes
Experiments were performed with L. monocytogenes strain 1043S, generously
provided by Dr. Chen Dong and Dr. Hao Shen.

The bacteria were first

inoculated onto brain heart infusion (BHI) agar plates containing 5µg/ml
erythromycin.

A single colony from the plate was inoculated into BHI

broth/erythromycin and grown overnight at 37°C.

A portion of the overnight

culture was reinoculated and grown to an optical density at OD600 = 0.1. The
bacteria were suspended in sterile PBS at a final concentration of 1X105/mL. A
volume of 200µl of bacteria (2x104 cells) was injected intravenously. Peripheral
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blood and tissue samples were collected 12 hours post-infection. The levels of
circulating neutrophils were determined by CBC, as described above. Tissues
were homogenized in sterile PBS containing 0.05% Triton X-100, serially diluted,
and plated on BHI agar to determine the number of colony forming units (CFU).
STAT3 inhibition
Before use, Stattic (Sigma) was dissolved in dimethylsulfoxide (DMSO; Sigma),
and diluted to a final concentration of 50µM in RPMI/10% FBS/1X AntibioticAntimycotic (Invitrogen).

Cells were pretreated with Stattic/DMSO or DMSO

alone for 1 hour at 37°C before treatment with 25ng/ml G-CSF for 6 hours.

Statistical analyses
Shown are mean values ± standard error mean (SEM).

P values were

determined by unpaired two-tailed Student’s t-tests using GraphPad Prism
version 5 for Mac OS X (http://www.graphpad.com). P values < 0.05 were
considered statistically significant.
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Chapter 3: G-CSF alters expression of chemokines in the bone marrow
microenvironment affecting neutrophil retention and release in a STAT3dependent manner

3.1. Background and rationale

G-CSF is administered clinically to boost circulating neutrophil numbers
by initiating their release from the bone marrow in a process called mobilization,
but its molecular mechanism of action is not fully understood. G-CSF lacks
intrinsic chemotactic ability, as its use in migration assays in vitro does not
induce murine neutrophil migration (139). Furthermore, G-CSF administration
into the peritoneal cavity is sufficient to induce neutrophil egress from the bone
marrow, but does not stimulate neutrophil migration to the site of injection (139).
Taken together, these data indicate that G-CSF likely acts through induction of
secondary effector molecules, possibly from generation of trans-acting signals
(115).
G-CSF administration in humans is reported to induce expression of IL-8
(CXCL8), a potent neutrophil chemoattractant (140). While there is no murine
IL-8, the chemokines KC (CXCL1) and MIP-2 (CXCL2) are considered its
functional homologues in the mouse, as all three bind the same receptor,
CXCR2, the major chemokine receptor expressed on the murine neutrophil
(141). KC and MIP-2, like IL-8, are primary mediators of neutrophil migration. In
addition to stimulating the release of neutrophils from the bone marrow, they can
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also induce their migration into the tissue (142). Il8rb-/- mice that are deficient in
CXCR2 exhibit high levels of peripheral neutrophils relative to their wild type
counterparts, likely due to the inability of neutrophils to marginate to the tissue,
resulting in their accumulation in the blood (130).
In contrast to the function of KC and MIP-2, SDF-1 (CXCL12) contributes
to the retention of hematopoietic cells in the bone marrow via interaction with its
receptor CXCR4 (118, 119). SDF-1 and CXCR4 are downregulated upon GCSF treatment, and while this response has been hypothesized to promote
neutrophil mobilization, the mechanism is unknown (120-122). Here we test
whether G-CSF/STAT3 signals regulate transcription of the chemokines MIP-2,
KC, and SDF-1, contributing to neutrophil mobilization.

3.2. Results

G-CSF-induced Cxcl2 expression in the bone marrow is mediated by Gr-1hi
mature neutrophils.

To test the role of STAT3 in regulation of neutrophil chemoattractants, we
analyzed the expression of KC and MIP-2 in the bone marrow microenvironment
of wild type and STAT3-deficient mice treated with G-CSF.
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Figure 3.1. G-CSF induces changes in chemokine expression in the bone
marrow microenvironment, which require STAT3. Wild type (WT, white bars)
and STAT3-deficient (KO, black bars) mice were treated in the absence (-) or
presence (+) of G-CSF at a dose of 250µg/kg for 24 hours before bone marrow
cells were harvested and analyzed by real-time PCR for expression of [A] Cxcl1
and [B] Cxcl2. Data shown are mean expression levels relative to Rpl13a (n≥4)
± standard error mean (SEM). *P < 0.05, **P < 0.01. This research was
originally published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang,
H. S. Li, and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory
response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2
expression and via modulation of CXCR2 signal transduction. Blood. 2010;115:
3354-3363. © the American Society of Hematology.

STAT3-deficient and wild type mice were injected with G-CSF or left
untreated, and total bone marrow was harvested 24 hours later, and analyzed by
real-time PCR for expression of Cxcl1 and Cxcl2, the genes that encode for KC
and MIP-2, respectively. We found that G-CSF induced upregulation of Cxcl1
and Cxcl2 in wild type bone marrow, with Cxcl2 expressed at a much higher
level than Cxcl1 (Figures 3.1[A] and [B]). However, this upregulation was not
detected in the STAT3-deficient mice, indicating a role for STAT3 in G-CSFinduced stimulation of Cxcl1 and Cxcl2 (Figures 3.1[A] and [B]). These data
suggest that STAT3 is required for G-CSF-induced regulation of chemokine
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expression in the bone marrow microenvironment, which may contribute to the
diminished neutrophil mobilization response of STAT3-deficient animals.
Next, we set out to determine which cells in the bone marrow are the
primary producers of Cxcl2. Because of the low levels of Cxcl1 detected in the
total bone marrow, and since Cxcl1 expression is thought to be mediated mostly
by fibroblasts, endothelial cells, and megakaryocytes (143-145), we focused on
analysis of Cxcl2 expression. Again, STAT3-deficient and wild type mice were
injected with G-CSF or left untreated, and total bone marrow was harvested 24
hours later. Because monocytes/macrophages and neutrophils are thought to
be the primary mediators of Cxcl2 expression under inflammatory conditions
(143, 146, 147), bone marrow cells were sorted into Gr-1- cells, monocytes (Gr1+ CD115+), immature neutrophils (Gr-1lo CD115-), and mature neutrophils (Gr1hi CD115-) (91, 148). Gr-1- cells and CD115+ monocytes expressed very low
levels of Cxcl2 (Figure 3.2).

This result is consistent with data from bone

marrow derived macrophages, which showed no G-CSF-induced expression of
Cxcl2 (data not shown).

By contrast, under basal conditions, Gr-1hi mature

neutrophils express the highest levels of Cxcl2 in the bone marrow (Figure 3.2).
G-CSF induces a 3-fold increase in Cxcl2 expression in immature neutrophils,
and nearly a 2-fold increase in mature neutrophils, with levels approximately 10fold higher than in the former (Figure 3.2).
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Figure 3.2. G-CSF-induced Cxcl2 expression in the bone marrow is
mediated by mature neutrophils. Wild type (WT, white bars) and STAT3deficient (KO, black bars) mice were treated in the absence (-) or presence (+)
of G-CSF at a dose of 250µg/kg for 24 hours before bone marrow cells were
harvested, sorted, and analyzed by real-time PCR for expression of Cxcl2 (n≥3).
Shown are mean expression levels relative to housekeeping gene Rpl13a ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

To verify expression of MIP-2 protein, immature and mature neutrophils
were sorted, and treated with G-CSF in vitro. Supernatants were collected after
24 hours, and analyzed for MIP-2 protein expression by ELISA. While MIP-2
levels were below the limit of detection in Gr-1lo immature neutrophils (data not
shown), approximately 150 pg/ml of MIP-2 was detected in the supernatants of
Gr-1hi mature neutrophils stimulated with G-CSF (Figure 3.3). Taken together,
these data demonstrate that G-CSF administration in vivo results in expression
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of Cxcl2 mRNA in the bone marrow, primarily mediated by Gr-1hi mature
neutrophils.

MIP-2 (pg/ml)
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Figure 3.3. G-CSF induces expression of MIP-2 protein in Gr-1hi cells. Wild
type Gr-1hi mature neutrophils were sorted, and stimulated in the absence (-) or
presence (+) of 25ng/ml G-CSF for 24 hours. The supernatant was harvested,
and analyzed for MIP-2 expression by ELISA (n≥3). Shown are mean values ±
SEM. (n.d. indicates not detected.)

G-CSF-stimulated neutrophil mobilization can be inhibited by a MIP-2
neutralizing antibody

To

demonstrate

that

MIP-2

mediates

G-CSF-induced

neutrophil

mobilization, we utilized a MIP-2-neutralizing antibody in vivo. We injected antiMIP2 or isotype control antibody intravenously 30 minutes before administration
of G-CSF, and analyzed neutrophil levels in peripheral blood 6 hours later. Mice
treated with IgG control antibody and G-CSF demonstrated a 3-4-fold increase
in peripheral neutrophils, while mice treated with MIP-2 neutralizing antibody
exhibited a 2-fold increase (Figure 3.4). Because MIP-2 neutralization dampens
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the neutrophil mobilization response to G-CSF, these results suggest that MIP-2
contributes to this pathway.

4000
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Figure 3.4. Use of a MIP-2-neutralizing antibody can block G-CSF-induced
neutrophil mobilization. Wild type C/57Bl6 mice were untreated (white bar), or
treated with 20µg IgG isotype control (black bar) or anti-MIP-2 (gray bar) 30
minutes prior to administration of 250µg/kg G-CSF. Data shown are mean
neutrophil levels per µl blood ± SEM, determined 6 hours after G-CSF treatment
(n≥3).

G-CSF-induced transcription of Cxcl2 is directly regulated by STAT3

To examine mechanisms of G-CSF-regulated Cxcl2 expression, we
analyzed the Cxcl2 proximal promoter, which revealed a putative STAT-binding
site approximately 200bp from the transcription start site (Figure 3.5[A]). To
examine whether STAT3 binds this site, chromatin immunoprecipitations (ChIPs)
were performed using 32D.G-CSFR cells, a murine myeloid progenitor cell line
(73). We found that G-CSF stimulation induced STAT3 recruitment to the Cxcl2
promoter within 30 minutes (Figure 3.5[B]). Next, a luciferase reporter construct
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was generated containing the proximal promoter sequence encompassing this
STAT site.

G-CSF induced a 3-fold increase in luciferase activity that was

suppressed by the co-expression of a STAT3 DNA-binding mutant that acts as a
dominant negative protein (STAT3-DN; Figure 3.5[C]) (77). Altogether, the data
support the idea that STAT3 directly binds the Cxcl2 promoter, controlling its
transcription.

Figure 3.5. STAT3 directly binds the Cxcl2 promoter, affecting its
transcription. [A] A schematic of the Cxcl2 gene, indicating the location of a
putative STAT-binding site in the proximal promoter region. [B] ChIPs were
performed on 32D.G-CSFR cells without (-) or with (+) G-CSF treatment for 30
min, using anti-STAT3 or IgG control antibody. Purified DNA samples were
subjected to real-time PCR to detect STAT-binding region in Cxcl2 promoter.
[C] 32D.G-CSFR cells were electroporated with pGL3-Cxcl2 and pTK-Renilla,
without (-) or with (+) pMX-STAT3-DN-IRES-GFP, treated in the absence (-) or
presence of (+) G-CSF for 6 h and assayed for luciferase activity. The ratio of
firefly:renilla relative light units (RLU) was averaged from three independent
experiments. Data shown are mean values ± SEM. *P < 0.05, **P < 0.01.
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G-CSF induces STAT3 binding to the Cxcl12 promoter; expression of
Cxcl12 in the bone marrow microenvironment is mediated by osteoblasts

In contrast to the roles of KC and MIP-2 in the neutrophil mobilization
pathway, SDF-1 is thought to mediate neutrophil retention in the bone marrow,
and its expression is downregulated upon G-CSF administration (120, 121). To
test the requirement for STAT3 in this pathway, total bone marrow cells were
isolated from wild type and STAT3-deficient mice with or without treatment with
G-CSF, and assayed for expression of Cxcl12, the gene encoding SDF-1.
Consistent with previous reports (120, 121), G-CSF administration suppressed
Cxcl12 expression in wild type mice (Figure 3.6). Interestingly, G-CSF treatment
resulted in a significant increase in Cxcl12 expression in STAT3-deficient mice
(Figure 3.6).
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Figure 3.6. G-CSF-induced downregulation of Cxcl12 is STAT3-dependent.
Wild type (WT, white bars) and STAT3-deficient (KO, black bars) mice were
treated in the absence (-) or presence (+) of G-CSF at a dose of 250µg/kg for 24
hours before bone marrow cells were harvested and analyzed by real-time PCR
for expression of Cxcl12. Data shown are mean expression levels relative to
Rpl13a (n≥4) ± SEM. *P < 0.05, **P < 0.01. This research was originally
published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang, H. S. Li,
and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory response to
CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and
via modulation of CXCR2 signal transduction. Blood. 2010;115: 3354-3363. ©
the American Society of Hematology.
The proximal promoter of Cxcl12 contains a putative STAT-binding site
approximately 500bp from the transcription start site (Figure 3.7[A]). Chromatin
immunoprecipitations were performed, which demonstrated that G-CSF induces
STAT3 to bind in the region of the putative STAT site in the Cxcl12 promoter
(Figure 3.7[B]). To identify the cell type that mediates Cxcl12 expression in the
bone marrow, bone fragments were digested with collagenase, and sorted into
four populations: lineage-positive cells (B220+ CD11b+ Gr-1+ CD3+ Ter119+),
endothelial cells (lin– CD45– CD31+), osteoblasts (lin– CD45– CD31– CD51+), and
progenitor cells (lin– CD45+). Consistent with a previous study (121), we found
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that osteoblasts are the primary cell type to express Cxcl12 (Figure 3.7[C]).
Further studies are required to identify the mechanism by which STAT3
regulates expression of Cxcl12 in osteoblasts.

Figure 3.7. STAT3 directly binds the Cxcl12 promoter, which is primarily
expressed by osteoblasts in the bone marrow microenvironment. [A] A
schematic of the Cxcl12 gene, indicating position and sequence of the putative
STAT-binding site. [B] ChIPs were performed on 32D.G-CSFR cells without (-)
or with (+) G-CSF treatment for 30 min, using anti-STAT3 or IgG control
antibody. Purified DNA samples were subjected to real-time PCR to detect
STAT-binding region in Cxcl12 promoter. Data shown are fold change when
pulled down with STAT3 compared to IgG control (n=3). [C] Bones were
isolated from wild type (WT) and STAT3-deficient mice (KO), and after removal
of bone marrow, were fragmented and digested with collagenase, then sorted
into hematopoietic lineage cells (lin+), CD45+ progenitor cells (45+), CD31+
endothelial cells (31+), and CD51+ osteoblasts (51+). Data shown are mean
Cxcl12 expression levels relative to Rpl13a ± SEM. (n≥3) *P < 0.05.

46

3.3. Discussion
As G-CSF stimulates neutrophil release from the bone marrow, we
demonstrate its effects on chemokine expression, likely affecting retention and
subsequent mobilization. In total wild type bone marrow, we show that G-CSF
upregulates the mRNA expression of the neutrophil chemoattractants Cxcl1 and
Cxcl2, while downregulating expression of the retention signal Cxcl12, as
summarized in Figure 3.8. Further examination of the cellular and molecular
mechanisms of Cxcl2 expression in the bone marrow revealed that it is directly
regulated by STAT3 and mediated by mature neutrophils. G-CSF induction of
MIP-2 expression is consistent with previous results demonstrating that G-CSF
does not directly stimulate neutrophil chemotaxis (139) and G-CSF-induced
neutrophil mobilization requires the action of trans-acting factors (115).
Additionally, patients receiving G-CSF treatments reported an increase in serum
levels of IL-8 (140), and knockouts of CXCR2, the IL-8 receptor in mice, do not
upregulate circulating neutrophils in response to G-CSF (142, 145). Several
recent reports support that KC and MIP-2 are produced in the bone marrow
upon G-CSF administration, but conflict as to the mechanism (145, 149). One
study demonstrated that G-CSF-induced MIP-2 expression in the bone marrow,
and MIP-2 protein was detected in the bone marrow supernatant, but attributed
the expression of MIP-2 to endothelial cells (149).

In Figure 3.2, we

demonstrated that the Gr-1- population also exhibited G-CSF-induced
expression of Cxcl2, but to a much lesser extent when compared to the Gr-1+
populations.

Another study described that G-CSF-induced upregulation of
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thrombopoietin (TPO) in the bone marrow, which in turn induced production of
KC and MIP-2 (145).

G-CSF did not directly induce this response in

megakaryocytes in vitro, but KC was expressed upon treatment with TPO (145).
Neutrophil mobilization in response to G-CSF was abrogated in CXCR2-deficient
mice, or upon addition of a CXCR2-neutralizing antibody (145).

Their

demonstration that G-CSF induces expression of KC and MIP-2 in the bone
marrow aligns with our results; however, we did not test the effects of direct
administration of TPO in our model, nor did we examine the contribution of
megakaryocytes. Collectively, our data and published findings support the idea
that G-CSF mediates neutrophil release by inducing expression of the
chemokines KC and MIP-2. Moreover, it was previously demonstrated in our lab
that both MIP-2- and G-CSF-stimulated neutrophil mobilization requires STAT3
(91, 150), further suggesting a functional relationship between these pathways.
In contrast to our MIP-2 findings, we showed that G-CSF suppressed
bone marrow Cxcl12 mRNA expression in wild type mice. Interestingly, G-CSF
stimulated an increase in Cxcl12 mRNA expression in STAT3-deficient bone
marrow. Because Cxcl12 mRNA levels closely follow SDF-1 protein levels, it is
thought expression of this gene is regulated transcriptionally (121).

Further

analysis revealed that STAT3 directly binds the Cxcl12 promoter, which is
consistent with a previous report demonstrating similar ChIP results in vascular
smooth muscle cells (151).

STAT3 may cause transcriptional repression of

Cxcl12, though this requires further testing. As basal expression of CXCR4 and
CXCR4-mediated chemotaxis are not affected in STAT3-deficient mice [A. D.
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Panopoulos and S. S. Watowich, unpublished results, and (150)], we
hypothesize that G-CSF/STAT3 signals regulate Cxcl12 expression and not
CXCR4 expression or signaling.

We demonstrated that osteoblasts are the

primary cells to express Cxcl12 in the bone marrow, in contrast to a previous
report also demonstrating its expression in endothelial cells (121). Others have
shown that G-CSF likely regulates SDF-1 expression by affecting the abundance
of osteoblasts (121, 126). Because osteoblasts develop from the mesoderm,
the contribution of STAT3 to their differentiation can be studied in vitro through
mesenchymal stem cells (152), which we did not address. Bone maintenance is
a dynamic process involving osteoblasts, the bone building cells, and
osteoclasts, which are responsible for bone resorption (153).

Therefore,

osteoblast numbers are regulated by osteoclasts, which share the monocyte
lineage (153).

This is the more likely scenario in our model, as

osteoclastogenesis, or the generation of osteoclasts, is shown to be indirectly
regulated by STAT3 (154), although this was not addressed in this study.
Another mechanism by which G-CSF may regulate SDF-1 expression is through
activation of proteolytic cleavage of SDF-1, as levels of proteases increase in
the serum after G-CSF administration (123-125).

While hematopoietic

progenitor cell mobilization was not affected in protease-deficient mice,
neutrophil mobilization was not directly tested, and thus the contribution of
proteases to this process is not fully understood (155). Taken together, our
findings indicate that G-CSF/STAT3 signals upregulate Cxcl1 (KC) and Cxcl2
(MIP-2) expression, while negatively regulating Cxcl12 (SDF-1), in the bone
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marrow of wild type animals, with Cxcl2 expression attributed to mature Gr-1hi
neutrophils and Cxcl12 expression implicated in osteoblasts. This is consistent
with the proposed role for these chemokines in the neutrophil mobilization
response. These data suggest that aberrant regulation of chemokine expression
in the bone marrow may contribute to the diminished neutrophil mobilization
response of STAT3-deficient animals.

Figure 3.8. A summary of the findings in Chapter 3. Neutrophils are
retained in the bone marrow, in part, via interaction between surface expression
of CXCR4 and SDF-1 in the bone marrow stroma (chiefly mediated by
osteoblasts). Administration of G-CSF induces neutrophil mobilization into
peripheral blood, which corresponds with STAT3-mediated downregulation of
SDF-1, and the concomitant production of MIP-2, primarily expressed by Gr-1hi
mature neutrophils.
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Chapter 4: STAT3 controls G-CSF-regulated expression of the chemokine
receptor CXCR2 in murine neutrophils

4.1. Background and rationale

In Chapter 3, we demonstrated the role for STAT3 in regulating G-CSFinduced expression of the chemokine Cxcl2; expression of its receptor CXCR2 is
also reportedly regulated by G-CSF (156), though the mechanism is not fully
understood.

It was also demonstrated that neutrophils require STAT3 for

efficient migration toward ligands of the chemokine receptor CXCR2 in vitro (91),
and Il8rb-/- mice (deficient in CXCR2) do not demonstrate G-CSF-induced
upregulation of circulating neutrophils (142). While there is evidence that STAT3
and G-CSF may regulate the CXCR2 response, such as CXCR2-driven
chemotaxis and CXCR2-mediated actin polymerization, the mechanisms are
unclear (91). In this chapter, we will examine how G-CSF/STAT3 signals control
CXCR2 expression and migratory response in neutrophils.

4.2. Results

G-CSF induces expression of l8rb in a STAT3-dependent pathway

To test the role of STAT3 in regulating expression of Il8rb, the gene
encoding CXCR2, we administered G-CSF in vivo, and measured Il8rb levels in
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total bone marrow.

We found that in wild type cells, G-CSF induced an

upregulation in Il8rb that was not detected in STAT3-deficient marrow (Figure
4.1).
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Figure 4.1. G-CSF stimulates Il8rb expression in the bone marrow in a
STAT3-dependent manner. Wild type (WT) and STAT3-deficient (KO) mice
were treated with G-CSF (250µg/kg; +) or left untreated (-) and bone marrow
samples were isolated after 24 hours, and analyzed by real-time PCR for
expression of Il8rb, relative to Rpl13a (n≥3). Data shown are mean values ±
SEM. This research was originally published in Blood. Nguyen-Jackson, H., A.
D. Panopoulos, H. Zhang, H. S. Li, and S. S. Watowich. 2010. STAT3 controls
the neutrophil migratory response to CXCR2 ligands by direct activation of GCSF-induced CXCR2 expression and via modulation of CXCR2 signal
transduction. Blood. 2010;115: 3354-3363. © the American Society of
Hematology.

As neutrophils are the primary cell type to express CXCR2 (130), we
tested the effects of G-CSF on CXCR2 expression in immature and mature
neutrophil subsets from wild type and STAT3-deficient mice at steady state. We
found that almost all mature Gr-1hi neutrophils expressed cell surface CXCR2
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and no significant differences were found between wild type and STAT3deficient cells (Figure 4.2[A] and [B]).

Figure 4.2. STAT3 is required for G-CSF-induced CXCR2 expression in
bone marrow Gr-1lo immature neutrophils. [A] Wild type (WT) and STAT3deficient (KO) mice were treated with G-CSF (250µg/kg; +G-CSF, bottom
panels) or left untreated (-G-CSF, top panels) and bone marrow samples were
isolated after 24 hours. CXCR2 expression in the Gr-1lo (left panels) and Gr-1hi
populations (right panels) is shown: WT (black line), KO (gray line). Isotype
controls are included (dashed black line). Data shown are from a representative
experiment (n≥3 for each group). [B] The average percentage of CXCR2positive cells within the bone marrow Gr-1lo and Gr-1hi subsets from untreated (-)
or G-CSF-treated (+) WT and KO mice is shown ± SEM (n≥3 for each group).
*P < 0.05. This research was originally published in Blood. Nguyen-Jackson, H.,
A. D. Panopoulos, H Zhang, H. S. Li, and S. S. Watowich. 2010. STAT3 controls
the neutrophil migratory response to CXCR2 ligands by direct activation of GCSF-induced CXCR2 expression and via modulation of CXCR2 signal
transduction. Blood. 2010;115: 3354-3363. © the American Society of
Hematology.
In contrast to mature cells, immature Gr-1lo granulocytes showed lower
levels of CXCR2 expression on the cell surface, as judged by differences in
mean fluorescence intensity (MFI) (MFI=1007 ± 126 for wild type Gr-1lo vs.
MFI=2877 ± 295 for wild type Gr-1hi neutrophils, P<0.001) (Figure 4.2[A]). As
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with Gr-1hi cells, there were no differences between wild type and STAT3deficient Gr-1lo cells. Consistent with cell surface expression, we found that Il8rb
mRNA levels were similar in wild type and STAT3-deficient immature Gr-1lo
granulocytes (Figure 4.3). Il8rb mRNA levels were significantly elevated in Gr1hi neutrophils, relative to immature granulocytes, and no obvious differences
were found between wild type and STAT3-deficient cells (Figure 4.3). These
data indicate that steady state Il8rb mRNA and CXCR2 protein amounts are
regulated during neutrophil differentiation, and the pathway that controls this
developmental expression is independent of STAT3. Hence, STAT3 appears to
be dispensable for regulation of CXCR2 expression during neutrophil
development in steady state conditions.
Studies from our lab and others suggest that the mechanisms regulating
neutrophils at steady state are distinct from those that operate in emergency, or
demand-driven, conditions that require G-CSF (19, 91, 93). Since STAT3 is
critical for emergency neutrophil responses (91), we tested whether it was
required to regulate CXCR2 in response to G-CSF administration. Wild type and
STAT3-deficient mice were treated with a single dose of G-CSF or left untreated,
and neutrophils were isolated and examined for CXCR2 expression by flow
cytometry or real-time PCR 24 hours later. These experiments showed that cell
surface CXCR2 expression was induced by G-CSF treatment in wild type
immature Gr-1lo granulocytes (Figure 4.2[A] and [B]). In mature Gr-1hi
neutrophils, G-CSF upregulated cell surface CXCR2 expression on wild type
cells compared to untreated controls (MFI=2877 ± 295 for untreated Gr-1hi vs.
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5212 ± 675 for Gr-1hi + G-CSF) (Figure 4.2[A] and [B]). In contrast to results in
wild type cells, G-CSF did not induce cell surface CXCR2 expression in STAT3deficient immature or mature neutrophil subsets (Figure 4.2[A] and [B]).
Furthermore, STAT3 was required for G-CSF-dependent upregulation of Il8rb
mRNA in Gr-1lo granulocytes (Figure 4.3).

Figure 4.3. STAT3 is required for G-CSF-induced Il8rb expression in Gr-1lo
immature granulocytes. WT and STAT3-deficient (KO) mice were untreated (-)
or treated with G-CSF (+) and bone marrow samples were isolated after 24
hours, and sorted into Gr-1lo and Gr-1hi subsets. Il8rb mRNA levels were
relative to the housekeeping gene Rpl13a. Shown are mean relative expression
levels ± SEM (n≥4). *P < 0.05, **P < 0.01, ***P < 0.001. This research was
originally published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang,
H. S. Li, and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory
response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2
expression and via modulation of CXCR2 signal transduction. Blood. 2010;115:
3354-3363. © the American Society of Hematology.
Because the bone marrow Gr-1lo population may also contain monocytes,
we re-analyzed CXCR2 expression in wild type and STAT3-deficient Gr-1lo cells
excluding those positive for CD115+ (macrophage colony-stimulating factor
receptor, or M-CSFR).

Gr-1lo CD115- cells comprise >80% of the Gr-1lo
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population, and similar patterns of CXCR2 cell surface and mRNA expression
relative to the total Gr-1lo subset were found (data not shown). Therefore, our
results indicate that STAT3 is necessary to enhance CXCR2 expression in the
immature Gr-1lo granulocyte subset during G-CSF administration in vivo, at least
in part via induction of Il8rb mRNA expression. Thus, our data collectively
indicate that STAT3 controls the induction of Il8rb mRNA and CXCR2 protein
amounts during systemic G-CSF administration, while being dispensable for
basal expression.
To examine the function of G-CSF-induced CXCR2 expression, immature
Gr-1lo and mature Gr-1hi granulocytes were isolated from G-CSF-stimulated or
untreated wild type and STAT3-deficient mice and chemotaxis was assayed in
response to MIP-2.

G-CSF treatment in vivo enhanced CXCR2-mediated

chemotaxis of immature and mature neutrophil subsets in both groups, although
the migratory response was significantly reduced in STAT3-deficient cells
relative to wild type (Figure 4.4). Wild type immature Gr-1lo granulocytes from
G-CSF-treated animals showed significantly more chemotactic activity toward
MIP-2, compared to Gr-1lo cells from untreated animals, while G-CSF-induced
chemotactic activity was attenuated in STAT3-deficient Gr-1lo granulocytes
(Figure 4.4).

These results are consistent with our previous observation of

effective mobilization of immature Gr-1lo neutrophils in wild type but not STAT3deficient mice upon G-CSF treatment (91).

Thus, our data collectively

demonstrate that STAT3 controls the induction of Il8rb mRNA and CXCR2
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protein in immature Gr-1lo granulocytes during systemic G-CSF administration,
correlating with their enhanced migratory potential.

Figure 4.4. G-CSF treatment in vivo enhances the neutrophil migratory
response to MIP-2. WT and STAT3-deficient (KO) mice were untreated (-) or
treated with G-CSF (+) and bone marrow samples were isolated after 24 hours,
and sorted into Gr-1lo and Gr-1hi subsets. The chemotaxis response of
immature Gr-1lo and mature Gr-1hi neutrophils to MIP-2 was determined by
Transwell assays. The average percentage of migrated cells compared to total
cells is shown ± SEM (n=5). **P < 0.01, ***P < 0.001. This research was
originally published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang,
H. S. Li, and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory
response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2
expression and via modulation of CXCR2 signal transduction. Blood. 2010;115:
3354-3363. © the American Society of Hematology.
STAT3 controls CXCR2 transcription by directly interacting with the Il8rb
promoter.

Analysis of the murine Il8rb and human IL8RB proximal promoters
revealed a putative STAT-binding site approximately 1300bp upstream of the
transcriptional start site (Figure 4.4[A]), potentially indicating similar regulation in
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the two species. The predicted transcriptional start site of Il8rb as identified by
Ensembl was verified by 5’-rapid amplification of cDNA ends (RACE) (data not
shown). Luciferase reporter constructs containing the proximal promoter region
encompassing the STAT site or a mutant STAT element (Figure 4.5[A]) were
generated. G-CSF treatment induced Il8rb reporter activity approximately 3-fold,

Figure 4.5. The putative STAT binding site in the Il8rb promoter controls GCSF-induced transcriptional activity. [A] A schematic of the Il8rb gene,
showing the location of the STATx site (top) and sequence of the mutant STAT
element (bottom). [B] 32D.G-CSFR cells were electroporated with wild type or
mutant pGL3-Il8rb and pTK-Renilla reporter plasmids, treated with or without GCSF for 6 hours and assayed for luciferase activity. The ratio of firefly:renilla
relative light units (RLU) in G-CSF-treated cells relative to unstimulated cells (G-CSF) was averaged from three independent experiments and shown ± SEM.
This research was originally published in Blood. Nguyen-Jackson, H., A. D.
Panopoulos, H. Zhang, H. S. Li, and S. S. Watowich. 2010. STAT3 controls the
neutrophil migratory response to CXCR2 ligands by direct activation of G-CSFinduced CXCR2 expression and via modulation of CXCR2 signal transduction.
Blood. 2010;115: 3354-3363. © the American Society of Hematology.
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relative to non-stimulated conditions (Figure 4.5[B]), indicating G-CSF activates
transcription from the Il8rb promoter. G-CSF-responsive Il8rb reporter activity
was suppressed upon mutation of the STAT site (Figure 4.5[B]), demonstrating a
role for this element in G-CSF-dependent transcription.
To examine whether STAT3 binds the Il8rb promoter in vivo, we
performed ChIPs in 32D.G-CSFR cells. These assays showed that STAT3 is
recruited to the Il8rb promoter upon G-CSF stimulation, similar to its inducible
interaction with the Socs3 promoter (Figure 4.6[A]). EMSAs with an
oligonucleotide containing the Il8rb STAT element revealed induction of a
specific

protein:oligonucleotide

complex

after

G-CSF

stimulation

that

supershifted upon incubation with a STAT3 antibody (data not shown). Taken
together, our data indicate that G-CSF-stimulated Il8rb transcription occurs by
direct binding of STAT3 to the Il8rb promoter.

Figure 4.6. STAT3 directly interacts with the Il8rb promoter. ChIPs were
performed on 32D.G-CSFR cells ± G-CSF treatment for 30 min, using antiSTAT3 or Ig control antibody, as indicated. Purified DNA samples were
subjected to PCR to detect Il8rb (top) or Socs3 (bottom) promoter sequences.
Data are representative of three independent experiments. This research was
originally published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang,
H. S. Li, and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory
response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2
expression and via modulation of CXCR2 signal transduction. Blood. 2010;115:
3354-3363. © the American Society of Hematology.
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The neutrophil mobilization response to infection with L. monocytogenes
is impaired in STAT3-deficient mice, resulting in prolonged infection.

To test whether the role for STAT3 in G-CSF- and MIP-2-responsive
neutrophil mobilization is indicative of STAT3 function during bacterial infection,
we assessed neutrophil mobilization in wild type and STAT3-deficient mice
following infection with Listeria monocytogenes.

It has been previously

demonstrated that clearance of this bacterium in vivo requires G-CSF (25, 94).

Figure 4.7. Impaired mobilization of STAT3-deficient neutrophils during L.
monocytogenes infection. Wild type (WT) or STAT3-deficient (KO) mice were
infected with L. monocytogenes by intravenous injection, as described in the
Methods. [A] At 12 h post-infection, circulating neutrophil numbers in peripheral
blood were determined by automated counting. Data shown are average fold
change in peripheral neutrophil numbers in infected vs. uninfected animals (n=5
for WT, n=4 for KO). [B] Spleens and livers were isolated 12 h after infection
with L. monocytogenes, homogenized, and cultured. Colony-forming units
(CFU) were enumerated 24 h after culture. Shown are mean CFU/organ (n=6
for WT, n=4 for KO). Error bars represent SEM. *P < 0.05. This research was
originally published in Blood. Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang,
H. S. Li, and S. S. Watowich. 2010. STAT3 controls the neutrophil migratory
response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2
expression and via modulation of CXCR2 signal transduction. Blood. 2010;115:
3354-3363. © the American Society of Hematology.
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Wild type mice rapidly induced circulating neutrophil numbers upon infection,
while peripheral neutrophil levels remained unchanged in STAT3-deficient mice
(Figure

4.7[A]),

suggesting

a

refractory

monocytogenes in the absence of STAT3.

mobilization

response

to

L.

Bacterial load was significantly

increased in the livers of STAT3-deficient mice relative to wild type animals at 12
hours post-infection, while no apparent differences were detected in spleen
(Figure 4.7[B]).

These results are consistent with a study that used a

granulocyte-depleting antibody during L. monocytogenes infection, which
demonstrated that neutrophils are important for bacterial clearance from the liver
at early stages (157). Furthermore, wild type mice were able to resolve the
infection 8 days later, while STAT3-deficient mice retained significant bacterial
burden, as assayed by CFU determinations (data not shown). These results
indicate that STAT3 is required for neutrophil mobilization in response to L.
monocytogenes, and suggest that the aberrant neutrophil response contributes
to an increased bacterial load in infected STAT3-deficient animals.

4.3. Discussion

Little is known regarding the regulation of chemokine receptor expression,
however dysregulated CXCR2-mediated neutrophil migration has been linked to
inflammatory conditions such as rheumatoid arthritis or chronic obstructive
pulmonary disorder, indicating the clinical relevance of examining CXCR2 (4, 6).
Basal

expression

of

CXCR2

is

STAT3-independent

and

controlled
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developmentally; however, we found that CXCR2 cell surface expression was
enhanced by systemic administration of G-CSF via a STAT3-dependent
pathway.

Examination of Il8rb transcriptional regulation revealed that it is a

direct STAT3 target, likely affecting G-CSF-induced expression in immature Gr1lo granulocytes, and its upregulation correlates with enhanced neutrophil
migration in vitro. This result is consistent with the observation that G-CSF
mobilizes immature neutrophils (91, 158, 159), a mechanism that contributes to
upregulation of circulating neutrophil levels. Overall, our results highlight an
additional mechanism used by G-CSF to influence neutrophil migratory activity,
which is illustrated in Figure 4.8.
Mutations in the DNA binding or transactivation domain of STAT3 are
linked to the primary immunodeficiency Hyper IgE Syndrome (HIES), also known
as Job’s Syndrome (160, 161).

In addition to having increased levels of

circulating IgE antibodies, these patients are susceptible to recurring bacterial
and fungal infections. This aspect of the HIES phenotype is consistent with
defective neutrophil function and, in fact, neutrophils isolated from HIES patients
have been shown to have impaired chemotaxis (162). In further support of our
findings in the mouse model, neutrophils isolated from HIES patients express
significantly reduced levels of CXCR2 (163).

Additionally, these neutrophils

have suppressed amounts of CXCR1 and the fMLP receptor, which recognizes
the formylated peptide Met-Leu-Phe (fMLP), a potent chemoattractant (163).
Although murine neutrophil migration in response to fMLP was not shown to
require STAT3 (91), and mice do not express CXCR1 (130), these findings
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suggest that aberrant neutrophil chemotaxis in patients with mutations in STAT3
can contribute to an immunosuppression that increases their susceptibility to
infections.
Consistent with the immunodeficiency in HIES patients, STAT3-deficient
mice are susceptible to infection with the bacterium Listeria monocytogenes
(Figure 4.7). While wild type mice are able to clear bacterial infiltrates in the liver
at 12 hours and recover from infection after 8 days, STAT3-deficient mice were
unable to do so (data not shown).
mediated

by

neutrophils

and

The innate immune response, which is

macrophages,

is

vital

to

suppress

L.

monocytogenes at early stages of infection. In line with previously published
results, we did not observe a significant difference in circulating monocyte levels
12 hours post-infection in wild type and STAT3-deficient mice, further supporting
that neutrophils are the primary responders at this time point [data not shown
and (157)]. Collectively, impaired neutrophil migration and reduced bacterial
clearance in infected STAT3-deficient mice are indicative of the importance of
neutrophil recruitment to suppress L. monocytogenes at early stages. STAT3regulated

pathways

in

granulocytes

require

additional

investigation

to

understand their potential contribution to HIES as well as other diseases with
aberrant neutrophil activity.
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Figure 4.8. A summary of the findings from Chapter 4. As neutrophils are
mobilized into peripheral blood from the bone marrow by G-CSF, one aspect of
this process involves the STAT3-dependent upregulation of the chemokine
receptor CXCR2. As STAT3-deficient mice are susceptible to infection by L.
monocytogenes, and do not upregulate neutrophils to the same extent as wild
type neutrophils in response to this pathogen, this pathway contributes to the
early-phase anti-bacterial immune response.
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Chapter 5: G-CSF/STAT3 signals control accumulation of H3K4me3 and
RNA polymerase II CTD pSer5 at the promoters of Cxcl2 and Il8rb

5.1. Background and rationale

We have established that two molecules responsible for neutrophil
migration, the chemokine MIP-2 and its receptor CXCR2, are regulated
transcriptionally by G-CSF/STAT3 signals.

While it is widely accepted that

STAT3 is a transcription factor, the mechanisms of its action at the chromatin
level are not fully understood.
Chromatin is the name given to describe DNA complexed with protein,
and is comprised of nucleosomes, which are formed when 146bp segments of
DNA is associated with a histone core, an octamer consisting of dimers of each
subunit: H2A, H2B, H3, and H4 (96). The tail at the amino terminus of each
histone subunit can be modified post-translationally, influencing transcriptional
activity of its associated DNA fragment by affecting accessibility of
transcriptional regulators. Recent attention has focused on the tri-methylated
lysines residues 4 and 27 of the histone subunit H3, denoted as H3K4me3 and
H3K27me3, which correlate with regions of active or repressed transcription,
respectively (96). To demonstrate the relationship between cytokine treatment,
transcription factor binding, histone modifications, and transcriptional activity, we
examine H3K4me3 and H3K27me3 levels in the STAT3-binding regions of the
Cxcl2 and Il8rb promoters, and test their responses to G-CSF.
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5.2. Results
The chromatin modifications of STAT3-binding regions in the promoters of
Cxcl2

and

Il8rb

exhibit

different

patterns

throughout

neutrophil

development

To examine the state of histone modifications at the STAT3-binding
regions of the Cxcl2 and Il8rb promoters, Gr-1lo immature and Gr-1hi mature
neutrophils were isolated, and H3 marks were analyzed by chromatin
immunoprecipitation utilizing antibodies against total histone H3, H3K4me3, and
H3K27me3. Interestingly, we found that levels of tri-methylation of H3K4 and
H3K27 varied at different stages of development at the same promoter. Figure
5.1 shows that in the Cxcl2 promoter, levels of activating H3K4me3 and
repressive H3K27me3 are equivalent in Gr-1lo cells, consistent with promoters
that are considered poised, in that they are transcriptionally inactive, but can be
readily activated (164). By contrast, the level of activating H3K4me3 marks is
significantly higher than repressive H3K27me3 marks in Gr-1hi cells, suggesting
this region of the promoter is constitutively open in mature neutrophils.
Activating H3K4me3 and repressive H3K27me3 marks exhibit a similar pattern
at the STAT3-binding region of the Il8rb promoter, with Gr-1hi cells possessing
significantly higher levels of H3K4me3 than Gr-1lo cells. These results suggest
that chromatin marks at the STAT3-binding regions of the Cxcl2 and Il8rb genes
are regulated developmentally, favoring an open configuration in mature Gr-1hi
cells. This is consistent with our previous results that expression of Cxcl2 and
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Il8rb is much higher in Gr-1hi cells (Figures 3.2 and 4.2, respectively) under
basal conditions, and the observation that neutrophils require maturation to gain
effector function (114).

Relative to Histone H3
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Figure 5.1. Histone modifications in the STAT3-binding regions of the
Cxcl2 and Il8rb promoters are developmentally regulated. Gr-1lo (LO) and
Gr-1hi (HI) neutrophil subsets were sorted from wild type mice, and analyzed by
chromatin immunoprecipitations using antibodies against H3K4me3 (white bars)
and H3K27me3 (hashed bars). Real-time PCR was used to amplify the STAT3binding regions in the Cxcl2 (left) and Il8rb (right) promoters. Data shown are
mean expression levels relative to total histone H3 ± standard error mean (SEM)
(n=3).

To confirm mRNA abundance of Cxcl2 and Il8rb under steady-state
conditions, Gr-1lo and Gr-1hi cells were isolated. Following the pattern of histone
modifications, both genes are more highly expressed in the mature Gr-1hi subset
(Figure 5.2). Interestingly, basal levels of Il8rb are much more abundant than
Cxcl2. These expression data correlate with the histone modification pattern
shown in Figure 5.1, and support the idea that high levels of H3K4me3, relative
to H3K27me3, are associated with active transcription.
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Figure 5.2. mRNA abundance of Cxcl2 and Il8rb is differentially regulated
under homeostatic conditions. Gr-1lo (LO) and Gr-1hi (HI) neutrophil subsets
were sorted from wild type mice, and analyzed for expression of Cxcl2 and Il8rb
mRNA. Data shown are mean Cxcl2 (left) and Il8rb (right) expression relative to
the housekeeping gene Rpl13a ± SEM (n=3). *P < 0.05.

C/EBPα, a transcription factor contributing to neutrophil differentiation,
acts as a transcriptional repressor in Cxcl2 and Il8rb reporter assays

We

then

investigated

the

possible

mechanisms

regulating

the

developmental differences observed in chromatin modifications at Cxcl2 and
Il8rb promoters (Figure 5.1). It was previously shown that C/EBP proteins, in
particular C/EBPα and C/EBPε, are differentially expressed throughout
neutrophil development (14).

Further examination of the Cxcl2 and Il8rb

promoters revealed that putative C/EBPα binding sites are very close (within
100-200bp) to the STAT3-binding regions (Figure 5.3).
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Figure 5.3. Putative C/EBPα-binding sites are in proximity to STAT3
binding sites in both Cxcl2 and Il8rb promoters. A schematic showing the
location and sequence of the putative C/EBPα-binding site, relative to the
STAT3-binding site, in the Cxcl2 (top) and Il8rb (bottom) promoters. The black
arrow indicates the transcription start site. Blue arrows indicate relative
positions of the primers used for STAT3, H3K4me3, H3K4me27, and H3 ChIP
assays. Green arrows indicate relative position of primers used for Pol II CTD
pSer5 ChIP.
C/EBPα has been shown to regulate transcriptional activity by recruiting
histone-modifying enzymes, and interacting with basal transcription factors
required for RNA Polymerase II activation (107, 165, 166).

Because of the

known role for C/EBPα during neutrophil development, and the proximity of its
putative binding site to the STAT3-binding site in the Cxcl2 and Il8rb promoters,
we examined the contribution of C/EBPα to the observed differences in mRNA
abundance. We first determined C/EBPα expression in Gr-1lo and Gr-1hi cells by
immunoblotting. While no difference was observed in total STAT3 or STAT3
phosphorylation in Gr-1lo and Gr-1hi cells, there was a striking difference in
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C/EBPα expression (Figure 5.4). Two C/EBPα protein sizes were detected in
Gr-1lo cells, likely the 30 kD and p42 kD species, in contrast to Gr-1hi cells, in
which only the 30 kD protein was detected. Encoded by an intronless gene,
C/EBPα can be translated into two products (167, 168). C/EBPα p30 translation
is initiated from a downstream AUG, and lacks one transactivation domain when
compared to the full-length C/EBPα p42 (167, 168). While C/EBPα p30 was
initially thought to function as a dominant negative of p42, there is recent
evidence that the two proteins may have distinct functions, as evidenced by
differing DNA-binding affinities, as well as regulation of unique sets of genes
(169-171).

Figure 5.4. C/EBPα exhibits a different expression pattern in Gr-1lo and Gr1hi neutrophil subsets. Gr-1lo and Gr-1hi neutrophil subsets were sorted from
wild type mice, and were left untreated (-) or treated with G-CSF (+) in vitro for
24 hours. Immunoblotting was performed using antibodies against C/EBPα,
phosphorylated STAT3 (pSTAT3), or total STAT3.
Results shown are
representative of at least three independent experiments.
To examine the effect of C/EBPα on transcriptional activity from the Cxcl2
and Il8rb promoters, a plasmid encoding C/EBPα was introduced into luciferase
reporter assays. The upstream promoter regions of Cxcl2 and Il8rb were cloned
into the pGL3-Basic luciferase vector, and assayed for reporter activity in
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response to G-CSF.

The Cxcl2 reporter demonstrated a five-fold increase in

reporter activity in response to G-CSF, which was further elevated upon addition
of a STAT3 plasmid (Figure 5.5[A]).

Interestingly, C/EBPα suppressed this

reporter activity, and this suppression was overcome by coexpression with
STAT3. In contrast to the Cxcl2 reporter, the Il8rb reporter required addition of
STAT3 in order to demonstrate G-CSF-responsiveness (Figure 5.5[B]). Addition
of C/EBPα alone did not affect the activity of this reporter, but when coexpressed with STAT3, there was a statistically significant reduction of activity
when compared to STAT3 alone.

These data suggest that expression of

C/EBPα, which is required for neutrophil differentiation and is expressed at
higher levels in Gr-1lo neutrophils, acts as a transcriptional repressor in reporter
assays.

These results may contribute to the difference in basal mRNA

abundance of Cxcl2 and Il8rb seen in Figure 5.2.

Figure 5.5. C/EBPα represses activity of Cxcl2 and Il8rb reporter
constructs. The proximal promoters of [A] Cxcl2 and [B] Il8rb were cloned into
the pGL3-Basic luciferase vector, and assayed for reporter activity in response
to G-CSF treatment for 12 hours. Reporters were co-expressed with plasmids
encoding STAT3 and C/EBPα, as indicated. Data shown are mean ratios of
firefly luciferase activity relative to renilla luciferase in untreated (NT) and G-CSF
treated samples ± SEM (n=3). *P < 0.05.
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G-CSF upregulates H3K4me3 at the STAT3-binding regions of the Cxcl2
and Il8rb promoters, and promotes accumulation of STAT3 and Pol II CTD
pSer5
To examine the effects of G-CSF stimulation on histone modifications in
the STAT3-binding regions of the Cxcl2 and Il8rb promoters, Gr-1lo and Gr-1hi
cells were isolated and treated with G-CSF in vitro, and H3 marks were analyzed
by ChIPs.

We demonstrate that while G-CSF has relatively little effect on

H3K27me3 abundance (two-fold or less), treatment with this cytokine results in
two- to four-fold upregulation of H3K4me3, relative to untreated samples, as
shown in Figure 5.6[A] and [B]. This result suggests that treatment with cytokine
correlates with increased accessibility to the transcription factor binding sites of
these promoters.

Figure 5.6. H3K4me3 accumulates in response to G-CSF treatment. Gr-1lo
(LO) and Gr-1hi (HI) cells were sorted from wild type mice, and were untreated
(NT, white bars) or treated with G-CSF in vitro for 6 (6 h, gray bars) or 18 hours
(18 h, black bars). Chromatin immunoprecipitations were performed using
antibodies against H3K4me3 and H3K27me3, relative to Histone H3. Real-time
PCR was used to amplify the STAT3-binding regions in the [A] Cxcl2 and [B]
Il8rb promoters (n=3). Data shown are mean values ± SEM.
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To test the kinetics of STAT3-binding to the Cxcl2 and Il8rb promoters in
primary immature and mature neutrophils, ChIPs were performed using a
STAT3 antibody.

We found that G-CSF stimulation correlates with STAT3

interaction at these promoters in both Gr-1lo and Gr-1hi cells.

In the Cxcl2

promoter, STAT3-binding appears to occur faster in mature Gr-1hi cells
compared to Gr-1lo cells (Figure 5.7[A]), whereas in the Il8rb promoter, binding
kinetics are equivalent in Gr-1lo and Gr-1hi cells (Figure 5.7[B]).

Figure 5.7. G-CSF leads to the recruitment of STAT3 to the Cxcl2 and Il8rb
promoters. Gr-1lo (LO) and Gr-1hi (HI) neutrophil subsets were sorted from wild
type mice, and were left untreated (NT) or treated with G-CSF in vitro for 6 (6h,
gray bars) or 18 hours (18h, black bars). Chromatin immunoprecipitations were
performed using antibodies against STAT3 and IgG control. Real-time PCR was
used to amplify the STAT3-binding regions in the [A] Cxcl2 and [B] Il8rb
promoters (n=3). Data shown are mean values ± SEM.
To further characterize the transcriptional activity of the Cxcl2 and Il8rb
promoters after G-CSF treatment, ChIPs were performed using an antibody that
detects phosphorylated serine 5 (pSer5) of the carboxy-terminal domain (CTD)
of RNA Polymerase II (Pol II), which is indicative of transcription initiation. The
kinetics of the recruitment of RNA Pol II CTD pSer5 (Figure 5.8[A]) and STAT3
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(Figure 5.7[A]) to the Cxcl2 promoter appears asynchronous, with accumulation
of H3K4me3 (Figure 5.6[A]) and pSer5 (Figure 5.8[A]) appearing before STAT3
(Figure 5.7[A]) in Gr-1lo immature cells.

By contrast, in Gr-1hi mature

neutrophils, H3K4me3 (Figure 5.6[A]) and STAT3 (Figure 5.7[A]) accumulate
with similar kinetics, while RNA Pol II CTD pSer5 (Figure 5.8[A]) is recruited
later. While these differences may contribute to the developmental differences
observed in Cxcl2 expression, further studies are required. In contrast to the
Cxcl2 promoter, recruitment of STAT3 (Figure 5.7[B]) and RNA Pol II CTD pSer5
(Figures 5.8[B]) to the Il8rb promoter follows similar kinetics in both Gr-1lo
immature and Gr-1hi mature neutrophils, suggesting a correlation between these
two events at this particular promoter. Interestingly, these two molecules are
recruited before accumulation of H3K4me3 (Figure 5.6[B]).

These results

indicate that expression of Cxcl2 and Il8rb may be regulated by distinct
mechanisms, and may account for the varying levels of expression that we have
observed. Taken together, however, the data demonstrate that G-CSF induces
changes in histone modifications by increasing H3K4me3, and results in the
recruitment of STAT3 and Pol II CTD pSer5 to the Cxcl2 and Il8rb promoters.
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Figure 5.8. G-CSF treatment leads to the recruitment of RNA polymerase II
CTD pSer5 to the Cxcl2 and Il8rb promoters. Gr-1lo (LO) and Gr-1hi (HI)
neutrophil subsets were sorted from wild type mice, and were left untreated (NT)
or treated with G-CSF in vitro for 6 (6h, gray bars) or 18 hours (18h, black bars).
Chromatin immunoprecipitations were performed using antibodies against Pol II
CTD pSer5 or IgG control. Real-time PCR was used to amplify the region
flanking the transcription start site in [A] Cxcl2 and [A] Il8rb (n=3). Data shown
are mean values ± SEM.

Inhibition of STAT3 phosphorylation blocks accumulation of H3K4me3 and
RNA Pol II CTD pSer5

The relationship between the accumulation of STAT3, Pol II CTD pSer5
initiation, and H3K4me3 at promoters is unknown.

To examine the role of

STAT3 in these events, the experiments above were repeated in the presence of
Stattic, a commercially available STAT3 inhibitor.

This in vitro approach to

STAT3 inhibition was used due to the technical limitations in obtaining sufficient
numbers of STAT3-deficient cells for these experiments.

Stattic specifically

inhibits the action of STAT3 by interacting with its SH2 domain, thereby inhibiting
its ability to become phosphorylated, dimerize, and bind downstream targets,
without affecting activation of other STATs (172).

To demonstrate whether
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Stattic affects total levels of STAT3 or histone H3, immunoblotting experiments
were performed, demonstrating that Stattic inhibited STAT3 phosphorylation
while STAT3 and H3 were unchanged (Figure 5.9).

Stattic exhibited toxic

effects in Gr-1hi cells at all timepoints, and in Gr-1lo cells at 18 hours, therefore,
we focused our attention on Gr-1lo cells treated with Stattic for 6 hours.

Figure 5.9. Stattic inhibits phosphorylation of STAT3. Gr-1lo immature
granulocytes were sorted and left untreated (- G-CSF) or stimulated with G-CSF
in vitro for 6 hours (+ G-CSF) in the presence of 50µM Stattic diluted in DMSO,
or DMSO alone. Immunoblotting was performed using antibodies against
phosphorylated STAT3 (pSTAT3), total STAT3, or total histone H3. Shown is a
representative experiment (n=3).
STAT3 and Pol II CTD pSer5 ChIPs with the Il8rb promoter were
repeated in the presence of Stattic, as these molecules were recruited by 6
hours (Figures 5.7[B] and 5.8[B]).

Figure 5.10 shows that while G-CSF

treatment in the presence of DMSO diluent induces STAT3 (Figure 5.10[A]) and
Pol II CTD pSer5 (Figure 5.10[B]) to interact with the Il8rb promoter, treatment
with Stattic inhibits this interaction.

These data suggest that STAT3

phosphorylation is required for accumulation of Pol II CTD pSer5, a reflection of
Pol II initiation.
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Figure 5.10. Stattic inhibits accumulation of STAT3 and pol II CTD pSer5 at
the promoter of Il8rb. Gr-1lo immature granulocytes were sorted and left
untreated (NT, white bar) or stimulated with G-CSF in vitro for 6 hours (6h) in the
presence of 50µM Stattic diluted in DMSO (black bar), or DMSO alone (gray
bar). Chromatin immunoprecipitations were performed using antibodies against
[A] STAT3 and [B] Pol II CTD pSer5, relative to IgG control (n=3). Data shown
are mean values ± SEM.
Similarly, to examine the role of STAT3 in the acquisition of H3K4me3 in
response to G-CSF at the Cxcl2 promoter, ChIPs using antibodies against
H3K4me3 were repeated in the presence of Stattic.

This time the Cxcl2

promoter was assayed because H3K4me3 accumulated at this promoter by 6
hours (Figure 5.6[A]). Again, G-CSF treatment correlated with upregulation of
H3K4me3 at the STAT3-binding region of the Cxcl2 promoter, which is inhibited
with the addition of Stattic (Figure 5.11).

This result suggests that STAT3

phosphorylation is required for tri-methylation of H3K4, associated with
transcriptional activation.
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Figure 5.11. Stattic inhibits acquisition of H3K4me3 at the Cxcl2 promoter.
Gr-1lo immature granulocytes were sorted and left untreated (NT, white bar) or
stimulated with G-CSF in vitro for 6 hours (6h) in the presence of 50µM Stattic
diluted in DMSO (black bar), or DMSO alone (gray bar).
Chromatin
immunoprecipitations were performed using antibodies against H3K4me3 or
total histone H3. (n=3) Data shown are mean values ± SEM.

5.3. Discussion

In this chapter, we examine the molecular events that occur as STAT3
binds the promoters of two genes important in the neutrophil migratory pathway,
Cxcl2 and Il8rb, which is summarized in Figure 5.12. We found that under basal
conditions, the ratio of activating H3K4me3 to suppressive H3K27me3 marks in
the STAT3 binding regions of these promoters varied, depending on stage of
development.

Correspondingly, basal mRNA abundance of Cxcl2 and Il8rb

were higher in Gr-1hi mature neutrophils compared to Gr-1lo immature
neutrophils, consistent with the idea that higher H3K4me3 relative to H3K27me3
correlates with active transcription.
To examine a potential mechanism contributing to this developmental
difference, the candidate transcription factors PU.1, C/EBPα, Gfi-1, and C/EBPε
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were evaluated, as these are the major transcription factors involved in
granulopoiesis (173). Immunoblotting revealed that expression of PU.1 and Gfi1 were similar in Gr-1hi and Gr-1lo cells, while expression of C/EBPα was
increased in immature cells and C/EBPε was upregulated in mature cells,
consistent with previous reports [data not shown, Figure 5.4 and (14)]. Upon
further examination of the Cxcl2 and Il8rb proximal promoters, putative C/EBPαbinding sites were found within 100-200bp of the STAT3-binding sites in both
promoters.

Co-expression of C/EBPα exhibited suppressive effects on the

reporter activities of both promoters.

This result is consistent with our

observation that higher levels of C/EBPα are expressed in Gr-1lo cells, which
demonstrate lower mRNA abundance of Cxcl2 and Il8rb compared to Gr-1hi
cells. We observed that Gr-1lo cells express a higher ratio of the two known
C/EBPα protein products, p42 to p30, relative to Gr-1hi cells.

It has been

reported that p42 and p30 have different functional activities, as p42, but not
p30, inhibited cellular proliferation (167), consistent with our observation that p42
exhibited suppressive effects in reporter studies.

While we did not test the

function of each protein species in our system, immunoblotting analysis revealed
that the C/EBPα plasmid utilized in our reporter assays predominately
expressed the p42 protein, consistent with our hypothesis (data not shown).
While C/EBPα p30 and p42 protein products can similarly regulate gene
expression in certain contexts (167), there is some evidence of divergent
functions, as p30 has only one of the two transactivation domains that p42
contains (167, 168). C/EBPα p30 was first described as the dominant negative
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form of p42 in regulation of the gene encoding G-CSFR (170), and
demonstrated reduced DNA-binding affinity (169).

However, it was later

reported that C/EBPα p30, but not p42, binds promoters of a group of genes,
indicating that p30 may have distinct functions (171). Recently, it was shown
that higher expression of C/EBPα p30 relative to p42 correlated with recruitment
of

subunits

of

polycomb

repressive

complex

2

(PRC2),

a

histone

methyltransferase that primarily mediates tri-methylation of H3K27 (165). While
these findings conflict with ours, as we demonstrate increased levels of p30 and
H3K4me3 in Gr-1hi cells, the results suggest that the two C/EBPα proteins
influence different chromatin modifying functions. While some explanations of
the C/EBPα mechanism in our model are consistent with these published
findings, they all rely on the premise that C/EBPα acts as a transcriptional
repressor, which has also been reported (174). Expression of C/EBPα p30 in
vivo relieved this repression (175), consistent with our observation that high
levels of p30 correlate with higher mRNA expression. While we demonstrate
that C/EBPα contributes to repression in our reporter assays, it is thought that
C/EBP family members are promiscuous and may have redundant roles (173).
Further studies are required to test the contribution of other C/EBP family
members in this system.
Examination of the STAT3-binding regions of the Cxcl2 and Il8rb
promoters revealed that G-CSF treatment promotes accumulation of H3K4me3,
STAT3, and Pol II CTD pSer5, which reflects Pol II initiation.

It has been

reported that G-CSF affects histone modifications, resulting in a MAP kinase-
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dependent increase in the acetylation of histone subunits H3 and H4 (176). GCSF has also been shown to promote an increase in H3K4me3 and H3K9
acetylation, another mark of transcriptional activation, through a C/EBPαdependent pathway (177). In this report, small hairpin RNA (shRNA)-mediated
knockdown of C/EBPα affected these chromatin modifications, but the
mechanism of recruitment was not examined (177).

Additionally, our

experiments with the STAT3 inhibitor Stattic demonstrate a reduction of
H3K4me3 at the Cxcl2 promoter in response to G-CSF, suggesting that STAT3
may be directly or indirectly involved in the recruitment of methyltransferases.
While the action of the transcription factors STAT3 and C/EBPα in the
recruitment of methyltransferases is not fully understood, STAT3 and C/EBPα
have both been shown to recruit p300 (108-112), a histone acetyltransferase
that may also recruit Pol II and components of the pre-initiation complex (178,
179). Additionally, it has been demonstrated that regions containing H3K4me3
were rapidly acetylated by p300 (180). Taken together, these data suggest that
the activity of transcription factors may directly result in histone acetylation, or
indirectly by first affecting histone methylation, which promotes activation of
transcription.
Ultimately, the goal of these studies is to understand how cytokines relay
the message to reorganize chromatin to allow transcription factors to have
access to promoters. While the mechanisms are not fully understood, we have
established the requirement of the transcription factor STAT3 in the
accumulation of H3K4me3 and Pol II CTD pSer5 upon activation by G-CSF.
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Figure 5.12. A schematic of the findings in Chapter 5. G-CSF treatment of
neutrophils results in the upregulation of H3K4me3. Correspondingly, STAT3
and Pol II CTD pSer5 are enriched at the promoter regions of Cxcl2 and Il8rb.
However, addition of Stattic, an inhibitor of STAT3 phosphorylation, blocks
recruitment of STAT3 and Pol II CTD pSer5 to these promoters. H3K4me3
upregulation is hampered. Taken together, the data demonstrate that STAT3
phosphorylation is required for accumulation of Pol II CTD pSer5 and H3K4me3
to the promoters of Cxcl2 and Il8rb.
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Chapter 6: General discussion and future directions

It has been previously demonstrated that G-CSF-mediated neutrophil
mobilization from bone marrow to peripheral blood is aberrant in mice harboring
a STAT3 deficiency in hematopoietic cells (91).
mechanisms are still unknown.

However, the molecular

In this dissertation, we have identified a G-

CSF/STAT3-mediated pathway that regulates mobilization by characterizing the
expression of the chemokines KC, MIP-2, and SDF-1, and the chemokine
receptor CXCR2. Furthermore, we determined the molecular events that occur
as STAT3 binds to the promoter regions of such genes.

6.1. G-CSF/STAT3-mediated induction of MIP-2 and CXCR2 contributes to
the neutrophil mobilization pathway

Under inflammatory conditions, neutrophils are the first recruited cells,
responding to chemokines and cytokines released locally, such as by resident
macrophages and dendritic cells (1).

To ensure a rapid response, mature

neutrophil effector cells are present in the blood under homeostatic conditions,
awaiting pro-inflammatory signals, including the chemokines KC and MIP-2,
which share the receptor CXCR2 in murine neutrophils (1). Expression of KC, or
keratinocyte chemoattractant, is attributed to fibroblasts, epithelial cells and
megakaryocytes, and not thought to be a major player in the bone marrow (143145). On the other hand, MIP-2 or macrophage inflammatory protein-2, was
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initially named for the major cell type to secrete it (146, 147).

Since then,

expression of MIP-2 has been reported in epithelial cells, endothelial cells, mast
cells, and neutrophils (147, 181-183).

KC and MIP-2 function to draw

neutrophils from the bone marrow into circulation, and from peripheral blood to
tissues under inflammatory conditions (139). It has been suggested that local
induction of chemokines at sites of inflammation is sufficient to induce monocyte
mobilization from bone marrow, but this has not been directly examined in
neutrophils (139). This possibility can be tested by labeling neutrophils in vivo,
and visualizing their migration to the tissue using live imaging techniques, where
a chemokine, such as KC or MIP-2, is directly administered.
Inflammation also triggers the upregulation of G-CSF, a cytokine present
in the serum at very low amounts under steady state conditions (35-37). The
ultimate function of G-CSF is to increase neutrophil output, which is achieved at
multiple levels, including increased proliferation of neutrophil progenitors,
differentiation, and mobilization into blood (38-40). Because G-CSF is a growth
factor that lacks direct chemotactic potential (139), it follows that G-CSF may
induce the expression of chemokines that would contribute to the neutrophil
mobilization response.

Indeed, we and others have shown that G-CSF

treatment elicits Cxcl1 (KC) and Cxcl2 (MIP-2) mRNA expression in bone
marrow (145, 149); we show the requirement for STAT3 in this pathway
(Chapter 3). Expression of MIP-2 in the bone marrow is primarily attributed to
mature Gr-1hi neutrophils, consistent with previous reports [Chapter 3 and (144,
184)]. This is a surprising result, given that the major target of MIP-2 under
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inflammatory conditions is also the neutrophil (144, 184). The autocrine effects
of MIP-2 production in neutrophils have not been tested, and can be done so in
vitro by examining the migratory potential (utilizing transwell assays) and the
signaling potential (measured by calcium flux), with or without pre-incubation
with MIP-2, similar to what has been previously published (185). Additionally,
because we demonstrated that G-CSF treatment in vivo enhanced the neutrophil
migratory response to MIP-2 (Figure 4.4), the inverse can be tested, to
demonstrate whether pre-treatment with MIP-2 results in increased sensitivity to
G-CSF. These experiments will demonstrate whether MIP-2 has priming effects
on neutrophils.
In addition, G-CSF/STAT3 signals are required to upregulate surface
expression of CXCR2, the receptor for KC and MIP-2, primarily in immature Gr1lo neutrophils (Chapter 4).

This result is consistent given that G-CSF

upregulates circulating immature granulocytes, in addition to mature cells (91,
158, 159). Il8rb-/- neutrophils do not respond to KC or MIP-2, suggesting that
CXCR2 is the major mediator of neutrophil chemotaxis (186). Because of the
redundant functions of KC and MIP-2, blocking one or the other is insufficient to
eliminate neutrophil-mediated pathologic inflammation.

Rather, targeting

CXCR2 would be a more effective means of controlling neutrophil infiltration.
Indeed, CXCR2-neutralizing antibodies, CXCR2 antagonists, and CXCR2
inhibitors are being developed to restrain neutrophil migration to the gut and
lungs, as well as to prevent tumor progression, since CXCR2 is the receptor for
IL-8, a pro-angiogenic factor in humans (187). Because STAT3 is characterized
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as a regulator in this pathway, this presents a novel target for therapeutics.
Inhibitors of STAT3 are being developed and used clinically, as STAT3 is
constitutively activated in many cancers, correlating with poor prognosis (172).
These inhibitors can be tested as anti-inflammatory drugs to treat conditions
where excessive neutrophil infiltration has been implicated, such as to the lungs
and the heart (132). Because STAT3 is ubiquitously expressed, tissue restricted
expression of the inhibitor would be ideal. For example, neutrophil elastase 2,
which has been used to promote neutrophil-specific expression of Cre in
conditional deletion models, can be exploited for tissue-specific expression of a
STAT3-inhibitor (188).
In a recent publication, Kohler et al. utilized intravital two-photon
microscopy to visualize neutrophil egress from the bone marrow and entry into
the vasculature (145).

In this system, EGFP expression was driven by the

lysozyme M (LysM) promoter, which enforces expression in myeloid cells. It
would be interesting to utilize this model, and examine MIP-2 expression in the
bone marrow by Gr-1hi mature neutrophils.

As LysM is also expressed in

monocytes and dendritic cells, it would be more specific to use a neutrophilspecific promoter, such as the aforementioned construct utilizing neutrophil
elastase 2 (Ela2) (188). Similarly, an Ela2-EGFP/MIP-2-YFP reporter mouse
could be generated, and G-CSF mobilization of neutrophils could be visualized
in a similar manner, but this time tracking chemokine production. This would
enable visualization of MIP-2 itself, and/or the cells that produce it, depending on
the intensity of the signal. This is similar to what was previously demonstrated
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using CXCR4-EGFP and SDF-1-EGFP (189). As ELR-CXC chemokines are
potent neutrophil chemoattractants with redundant functions, it would be
interesting to exploit this conserved region to visualize all chemokines that act in
this pathway. A fluorescent probe can be generated against this conserved
sequence, and antibodies can be used to distinguish individual chemokines for
further study, if necessary.
The inability of mice with a STAT3 deficiency in hematopoietic cells to
enhance peripheral blood neutrophil numbers upon G-CSF or MIP-2 treatment
suggested a defective mobilization response (91, 150).

However, STAT3-

deficient mice are neutrophilic under basal conditions, which suggests that
existing high levels of circulating neutrophils may prohibit further upregulation.
Because we previously showed that G-CSF treatment over 5 days induces
approximately a ten-fold increase in peripheral blood neutrophils in both wild
type and STAT3-deficient mice, this result indicates that circulating neutrophil
amounts are not saturated in STAT3-deficient animals under basal conditions
(91). An alternative explanation for the neutrophilia is found by examining the
ability of STAT3-deficient neutrophils to migrate to the tissue, as blocks in the
pathway would result in their accumulation in the blood. We found that MIP-2
treatment caused a significant reduction of bone marrow neutrophils in wild type
mice, but these levels were unaffected in STAT3-deficient animals (150). We
hypothesized that the drop in bone marrow neutrophils in the wild type mice
would result in their accumulation in peripheral blood or spleen, but they did not,
indicating that MIP-2 likely induced neutrophils to marginate to other tissues
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(150).

Because neutrophils were retained in the bone marrow of STAT3-

deficient mice upon MIP-2 administration, these results suggest that STAT3 is
required for MIP-2-mediated neutrophil mobilization to peripheral blood as well
as margination to non-hematopoietic tissues (150). Our findings are consistent
with impaired CXCR2-mediated chemotaxis of STAT3-deficient neutrophils in
vitro, which was previously described by our group (91). Further analysis of this
hypothesis can be performed by utilizing in vivo imaging techniques to track
neutrophil egress from bone marrow to blood, and from circulation to peripheral
tissues.
In an attempt to address the neutrophilia in STAT3-deficient mice under
steady-state conditions, chimeric mice can be generated by transferring bone
marrow from STAT3-deficient mice into wild type mice. This is similar to what
was tested in Il8rb-/- mice deficient in CXCR2, which also demonstrate basal
neutrophilia (149). Analysis of the chimera revealed that Il8rb-/- mice exhibited
increased neutrophil retention in the bone marrow, indicating a novel function for
CXCR2 that had not yet been studied (149). Furthermore, the Cre-promoter in
our system is driven by TIE-2, which is expressed by bone marrow and
endothelial cells. Therefore, to understand the contribution of STAT3-deletion in
only the neutrophils, incorporation of neutrophil elastase 2-Cre can ensure
specific deletion (188).
To explore whether STAT3 is involved in propogation of signals
stimulated by MIP-2, these pathways were studied in wild type and STAT3deficient neutrophils in our laboratory. While STAT3 was dispensable for AKT
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signaling and calcium flux in response to MIP-2, STAT3 appeared to control the
amplitude of phosphorylated c-Raf, MEK 1/2, and ERK 1/2 [A. D. Panopoulos
and S. S. Watowich, unpublished results and (150)]. Addition of the MEK 1/2
inhibitor U0126 significantly affected MIP-2-mediated migration in vitro (150).
Taken together, these data indicate that STAT3 specifically regulates the
Raf/MEK/ERK cascade downstream of MIP-2. As this pathway is required for
MIP-2 mediated neutrophil migration, these results may contribute to the
defective neutrophil mobilization observed in STAT3-deficient mice.

The

mechanism by which STAT3 activates the MAP kinase pathway has not yet
been defined. However, there is speculation that STAT3 regulates scaffolding
proteins and/or regulatory proteins for Rho GTPase family members, which have
been implicated in ERK signaling (190, 191). A recent report demonstrated that
STAT3 regulates activity of the Rho GTPase Rac1 in mouse embryonic
fibroblasts by interacting with βPIX, a guanine nucleotide exchange factor (192).
While further studies are required in myeloid cells to determine the mechanism
by which STAT3 controls MAP kinase signaling, these results indicate another
dimension of neutrophil mobilization that is regulated by STAT3 that could be
exploited clinically, as MAP kinase small molecule inhibitors are currently being
developed to treat cancers and inflammation (193).
Collectively, the data demonstrate that G-CSF, MIP-2, and KC are potent
neutrophil mobilizing agents, which are an important aspect of innate immunity.
Further work is needed to understand these mechanisms, enabling the
development of targeted therapies against chronic inflammatory conditions due
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to excessive neutrophil numbers.

Additionally, these mechanisms can be

exploited to treat conditions of immunodeficiencies due to insufficient neutrophil
numbers.

6.2. Overcoming SDF-1-mediated retention signals in the bone marrow is
required for CXCR2-stimulated neutrophil release

It has been shown that G-CSF signals result in downregulation of
CXCR4/SDF-1, relieving neutrophil retention in the bone marrow and allowing
their release (120-122). We demonstrate that STAT3 is specifically required for
G-CSF-induced regulation of SDF-1 in the bone marrow, but the mechanism of
this pathway is not fully understood (Chapter 3).

First, it is unclear how

elimination of a retention signal results in migration out of the bone marrow;
most likely a second migratory signal is also required. Although use of the
CXCR4 antagonist AMD3100 is sufficient to mobilize neutrophils, its mechanism
of action has not been elucidated.

It was demonstrated that treatment with

AMD3100 resulted in an enhanced response to KC and MIP-2, supporting the
idea that the two pathways are distinct, and dependent on one another (139).
However, the effects of KC and MIP-2 on SDF-1 expression have not been
tested, neither has chemokine production as a result of AMD3100 treatment
been examined. Secondly, as previously discussed in Chapter 3, it is not known
how CXCR4 and SDF-1 are downregulated by G-CSF. We have demonstrated
that the likely target of G-CSF is SDF-1, but not CXCR4 (A.D. Panopoulos and
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S. S. Watowich, unpublished results, and Chapter 3).

Thus, future studies

should be focused on the pathways that regulate SDF-1 expression. It was
previously shown that SDF-1 expression in the bone marrow directly correlates
with abundance of osteoblasts, which are cells associated with building bone
(121, 126).

Therefore emphasis should be placed on osteoblasts and their

regulatory cells, the osteoclasts (153). Because osteoblasts develop from the
mesoderm, differentiation of mesenchymal stem cells should be studied in vitro
using STAT3-deficient cells to examine the requirement for STAT3 in this
pathway

(152).

Parallel

studies

should

be

performed

to

examine

osteoclastogenesis, or the development of osteoclasts from monocyte
progenitors, as PIAS3, a negative regulator of STAT3 signaling, has been
implicated in this pathway (153, 154). These studies would not only further
demonstrate the pathways that contribute to neutrophil mobilization, they would
also contribute to our understanding of hematopoietic progenitor stem cell
(HPSC) mobilization for transplantations, as AMD3100, G-CSF, and chemokines
such as MIP-2 (usually designated in the clinic as GRO-β) are utilized clinically
for this purpose (50, 142, 194). While no direct studies comparing neutrophil
and HPSC mobillzation have been performed, the two pathways are thought to
be linked, as they are mediated by the same agents, but exhibit different
kinetics, with neutrophil mobilization occurring earlier (50, 142).
There is also the possibility that the CXCR4 and CXCR2 axes exhibit
crosstalk. Treatment of neutrophils with CXCR2 ligands desensitizes CXCR4
signaling (185), but the mechanism was not established.

Protein kinase C-
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epsilon (PKC-ε) was implicated in the cross-desensitization of chemokines
receptor signaling, but this possibility requires further testing in our model (195).
Additionally, neutrophils from Il8rb-/- chimeric mice do not mobilize to AMD3100,
further indicating a relationship between the two pathways (149).
The baseline neutrophilia exhibited in STAT3-deficient mice has been
attributed to impaired expression of the negative regulator SOCS3, a STAT3
target gene; however, the mechanism of the neutrophilia in Il8rb-/- has not been
demonstrated (88, 130). It was suggested that activation of CXCR2 results in
negative feedback signaling to slow neutrophil production, but this has not been
tested (130).

Future studies examining the effects of CXCR2 activation on

neutrophil proliferation and differentiation are required to examine if CXCR2
initiates a negative feedback program. It is known that mobilizing neutrophils
upregulate CXCR2 and downregulate CXCR4 [Chapter 4 and (196)]; perhaps
uncovering common regulatory or signaling pathways between these two
receptors would lead us to their involvement in a negative feedback loop.
Additionally, in β2-integrin-deficient mice, which also demonstrate basal
neutrophilia

and

impaired

neutrophil

mobilization

responses,

excessive

neutrophils are released from the bone marrow, and G-CSF and IL-17 levels
were elevated in the serum and plasma, respectively (197, 198).

However,

antibodies blocking G-CSF and IL-17 reduced the observed neutrophilia in these
mice (197, 198), indicating to the authors that neutrophil egress from the bone
marrow may initiate a negative feedback loop to dampen expression of G-CSFand IL-17 (197, 198). Further studies are required to establish this mechanism.
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To begin with, it may be helpful to perform microarray analysis to compare bone
marrow neutrophils and circulating neutrophils under steady-state conditions and
mobilization-stimulated conditions (either by G-CSF or chemokines). This would
reveal whether the mobilization-stimulated circulating neutrophil expresses antineutrophil production factors, such as anti-G-CSF or anti-IL-17.
The actions of KC, MIP-2, and SDF-1 to promote the migration and
retention of neutrophils are well established.

However, whether the two

pathways exhibit crosstalk is not understood, and further analysis will promote
our understanding of chemokine function, ultimately adding to our understanding
of neutrophil and HPSC mobilization.

6.3. Activation of STAT3 contributes to the recruitment of histone
methyltransferases and RNA Polymerase II

The association of DNA with histones results in a highly compacted
structure. While some transcriptional regulators are able to bind DNA in this
state, others require DNA to be dissociated from histones (99). This involves a
dynamic process of DNA-histone association and dissociation as transcription
progresses (99). The relationship between recruitment of transcription factors
and the transcription pre-initiation complex (PIC), including RNA Polymerase II,
is unknown. Furthermore, the relationship between the different types of histone
modifications, such as methylation and acetylation, is unknown. It has been
demonstrated that transcription initiation “takes a village”, requiring the
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coordinated action of a large complex of proteins, but there is much that remains
to be understood (199).
We demonstrate that the interaction of STAT3 with the Il8rb promoter
follows similar kinetics as onset of RNA Polymerase II initiation, demonstrating
that the recruitment of these proteins may be linked. As these experiments were
performed using an antibody against Pol II CTD pSer5, a residue that becomes
phosphorylated upon Pol II initiation, this result does not clarify when Pol II was
recruited. These ChIP experiments should be repeated using antibodies against
Pol II.

Additionally, ChIPs can be performed using antibodies against

components of the transcription PIC, such as TFIID, which is the first factor
recruited to the PIC (104). Alternatively, studies utilizing deletion mutants of
STAT3 can be utilized to map the region of STAT3 required for recruitment of
the PIC.

For example, the transactivation domain (TAD) of STAT3 may be

important in recruitment of co-activators, and deletion of this region and
overexpression of this truncated protein would reveal its function in this process.
Our studies further show that inhibition of STAT3 phosphorylation blocked
the recruitment of Pol II CTD pSer5, as well as the accumulation of H3K4me3,
supporting the idea that activation of STAT3 is required for recruitment of
methyltransferases. Further studies are required to examine the relationship
between STAT3 phosphorylation and the recruitment of methyltransferases.
While there are many methyltransferases, one in particular, mixed-lineage
leukemia (MLL), has been implicated in myeloid cells and is responsible for
H3K4 methylation, and has also been shown to interact with Pol II (200). STAT3
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interaction with MLL should be examined, either by co-immunoprecipitations or
re-ChIP (ChIP first with anti-STAT3, then before breaking crosslinks, pull-down
with anti-MLL). Similarly, these experiments can be repeated to detect other
histone-modifying enzymes that are recruited upon G-CSF stimulation.
Alternatively, microscopy techniques can be used to examine whether STAT3
and histone modifying enzymes co-localize in activated cells. These pathways
have practical applications, for example 5-azacytidine, a cytidine analogue that
inhibits the activity of methyltransferases, is used as a treatment for
myelodysplastic syndrome, a condition of aberrant myeloid cell differentiation
(201).
While techniques like ChIP-sequencing (ChIP-Seq) or ChIP combined
with microarray analysis (ChIP on chip) would be very interesting, the data
would indicate the DNA that is associated with the protein (for example, STAT3)
for which we are assaying. Another method, such as co-localization studies
utilizing detecting STAT3 and histone modifying enzymes, would demonstrate if
these proteins are associated with similar regions of DNA. Rather, I would be
more interested in exploring the proteins associated with STAT3 as it binds
promoters. Co-immunoprecipitations between STAT3 and general transcription
factors or other candidate transcription regulators can be tested. Alternatively,
ChIP can be combined with protein detection experiments. For example, after
stimulating cells to activate STAT3 and associate with DNA, and pulling down
with anti-STAT3, this protein complex and be separated on gels, and examined
for protein species such as by Coomassie blue staining. Depending on the
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protein size, antibodies against candidate proteins can be used for
immunoblotting. The Proteomics Core Facility at UT MDACC has the capability
to perform in-gel digestion coupled to peptide sequencing to identify unknown
proteins. This facility can also perform various types of mass spectrometry to
identify proteins complexed with STAT3.
The simplified view that transcription is activated merely upon binding of
transcription factors is proving to be outdated, as it is now understood that this
process is very complicated, involving many, possibly hundreds, of different
proteins (199). Although STAT3 is generally thought of a transcription activator,
it has been proposed that a splice variant can act as a repressor (202).
Regardless, the prevailing thought is that STAT3 likely coordinates its function
with other proteins, forming a major complex that is called an enhanceosome
(203, 204). The enhanceosome then, together with co-activators and histone
modifying enzymes, increases transcription initiation (203, 204). Thus, further
studies are required to understand the basic function of STAT3 as transcription
is activated.

6.4. Summary

In this dissertation, we have demonstrated the requirement for STAT3 in
the neutrophil mobilization pathway, as STAT3 regulates G-CSF-induced
expression of MIP-2 and suppression of SDF-1 (Figure 3.8), as well as
simulation of CXCR2 (Figure 4.8).

Further study of the mechanism of
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chemokine regulation will reveal novel targets to address the balance between
immunodeficiency and pathologic inflammation. Also, understanding neutrophil
mobilization may reveal aspects that are common to HPSC mobilization, as both
are stimulated by the same agents. We also demonstrate the requirement for
phosphorylated STAT3 in the acquisition of G-CSF-induced H3K4me3 and
recruitment of Pol II CTD pSer5 (Figure 5.12). Future detailed studies of STAT3
regulation of transcription will add to the understanding of general transcription
initiation processes, as epigenetic inhibitors are now being used clinically.
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